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CHAPTER 1 
INTRODUCTION 
AND 
AIMS OF THE THESIS 
Chapter 1 
Menopause is defined as the last menstrual bleeding. Menopause is the inevitable 
consequence of the ageing process of the ovarían function. Already 20 weeks after 
conception this process begins, and the initial amount of 5 to 7 million primordial follicles 
is reduced to about 10% at birth, and about 5% at the moment of menarche [1]. Of the 
remaining 300.000 follicles only about 400 fully mature and reach the moment of 
ovulation. The rest of the remaining follicles degenerates. 
For a woman menopause means the cessation of the reproductive years. The 
average menopausal age is 51 years (range 46 - 55 years), and this has not changed much 
during the last decades [2,3]. The diagnosis of menopause can only be made in retrospect, 
and nowadays it is generally accepted that at this age a woman can be considered 
postmenopausal after one year of amenorrhea. After one year of amenorrhea the 
probability of having another menses is about 5% [4]. Average life expectancy for women 
is 81 years, so a woman can expect to live more than one third of her life in the 
postmenopausal state. 
Menopause, and the problems accompanying the climacteric period, are 
phenomena that can be expected in an increasing number of women during the following 
decades. The 20th century has increased mean life expectancy amongst others by the 
introduction of modem medicine and improvement of hygiene and nourishment. 
Therefore, the number of postmenopausal women is now about four-fold higher than in 
the year 1900, and it is expected to double once more until the year 2030 [5-7]. 
The years around menopause, called the climacteric period, very often are 
accompanied with symptoms and complaints as hot flushes and sweats [8], due to the 
decreasing oestrogen concentrations with at the same time supraphysiological follicle 
stimulating hormone concentrations [9,10]. The oestradiol concentrations may fluctuate 
and this reportedly is the main cause of the hot flushes and sweats [11,12], although this 
mechanism has been questioned [13]. Anovulation and luteal insufficiency may be 
associated with dysfunctional bleeding. About 85% of climacteric women experience 
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climacteric problems to some degree; 25% of them seek medical care [14]. 
The climacteric signs and symptoms mentioned before vary with the cultural 
background [15]. They may often lead to secondary less typical problems, some of which 
may also be experienced independently, but they may all interfere with the feeling of 
well-being [16]. Complaints as sleeplesness, fatigue, mood changes, and sexuality 
problems, are often associated with the hormonal changes, but they may, however, very 
well be related to psychosocial problems that accompany the ageing woman, like the 
"empty nest syndrome" and furthermore the changing self-image of becoming an older 
women. These changes may alter the woman's life perspectives. 
Little is known about the way menopause was experienced in the past. During the 
last decades the phenomena around the menopause gained more interest, and it became 
clear that climacteric symptoms and complaints are a result of the change in hormonal 
homeostasis. By some authors, the climacteric was defined as an oestrogen deficiency 
syndrome or even an endocrinopathy [17], an illness that needs hormonal treatment. 
Others, however, do emphasize the natural character of menopause, which does not need 
treatment, but needs understanding, acceptance and re-orientation on a new phase of life 
[18]. The choice for hormonal treatment of climacteric and postmenopausal complaints, 
also called hormone replacement therapy, is troubled by classical reports on increased risk 
for thrombo-embolic and cardiovascular complications like those reported for oral 
contraceptives [19,20], and the possibility of increased risk for breast cancer [21] or 
endometrial cancer [22]. 
In general, perimenopausal women are often experiencing many signs and 
symptoms. Some may also be related to the ageing process, and are not solely due to the 
oestrogen deficiency. However, ongoing research and experimental treatment with 
oestrogens gradually revealed that typical climacteric complaints, such as flushes and 
sweats, and urogenital problems, can be relieved very effectively with hormone 
supplementation [23-31]. 
Climacteric signs and symptoms introduce new complaints and may aggravate 
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already existing problems. Hormone replacement therapy obviously can not solve all the 
problems related to ageing, but it clearly may help to relieve serious symptoms, and by 
doing so it may also strengthen the climacteric woman in coping with the other ageing 
related problems. 
Next to the relief of the symptoms and complaints mentioned before, there are 
long-term events that may impair women's health and well-being. Women after 
menopause are increasingly at risk for osteoporotic fractures and cardiovascular morbidity 
and mortality associated with the oestrogen deficiency. Administration of natural 
oestrogen reverses these risks [32-58] and forms another indication for hormone 
supplementation. This preventive treatment gains in popularity, but it is clear that the 
benefits of the preventive aspects should be balanced against possible disadvantages of 
hormone replacement therapy. 
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AIMS OF THIS THESIS 
Our understanding of the events taking place at menopause has increased. Much 
more is known about the benefits and possible disadvantages of hormone replacement 
therapy. It has also become clear that hormone replacement therapy may have a profound 
impact on the chance of developing cardiovascular disease and osteoporosis. 
Consequently, the number of women seeking hormone replacement therapy has increased 
tremendously. Still, many aspects of hormone replacement therapy are greatly obscure, 
the hypotheses put forward on cause/relationship of several events are being disputed, and 
also our knowledge concerning negative aspects of hormone replacement therapy is still 
insufficient, thereby worsening to formulate the benefit/risk ratio of this type of 
treatment. 
The aims of this thesis are therefore, (1) to investigate several metabolic aspects of 
various combined oestrogen/progestogen replacement therapies with regard to the risk of 
developing atherosclerosis, and with special reference to the additional influence of the 
progestogen, furthermore (2) to investigate the effects of combination hormone therapy on 
several histological aspects of the endometrium and (3) to gain insight into factors 
determining women's compliance for such a hormone treatment regimen. 
As a base for these studies (4) we thoroughly reviewed the available literature 
concerning the relevant aspects of hormone replacement therapy as: indications and 
contra-indications, the cardiovascular impact, and some possible underlying pathogenetic 
mechanisms. Thereafter, benefits and risks will be balanced, and finally, the role of 
progestogens, and its consequences for patient compliance and acceptance will be 
addressed. 
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HORMONE REPLACEMENT THERAPY 
A REVIEW 
Chapter 2 
The purpose of hormone replacement therapy in postmenopausal women is to 
restore serum oestradiol concentrations to those seen in the early follicular phase of the 
menstrual cycle (about 200 - 250 pmol/l). Hormone replacement therapy can be 
administered as local and systemic treatment. Local applications, such as creams and 
vaginal suppositoria, are appropiate for the treatment of urogenital symptomatology, such 
as atrophic vaginitis, but normally the blood levels achieved by such treatment are too 
low to establish an effective relief of the other climacteric symptoms or to achieve the 
preventive purposes. Systemic hormone replacement therapy is possible by oral, 
transdermal (patch or cream), subcutaneaus and intra-muscular administration. As in local 
treatment, the effects are dose dependent. Regardless of its formulation or route of 
administration, most women can effectively be treated [1-18]. With oral dosages of 0.6 
mg conjugated oestrogen, or 2 mg micronised 17fl-oestradiol or oestradiol-valerate the 
serum oestradiol concentrations specific for the early follicular phase of the menstraul 
cycle can be attained. 
INDICATIONS 
The main indications for systemic hormone replacement therapy [19-30] can be 
categorized in: climacteric complaints, typical and atypical, oestrogen deficiency 
complaints, and long term events. Table I describes each category in more detail. 
The most typical climacteric complaints, as hot flushes and sweats, are obviously 
related to the hormonal imbalance and appear to respond well on oestrogen 
supplementation [1-15]. Treatment for one to two years, and if necesarry longer, may 
help the women to overcome these problems. 
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Table I: 
Climacteric 
complaints 
Oestrogen 
deficiency 
complaints 
Long term 
events 
Indications for hormone replacement therapy 
Tvpical 
complaints: 
- hot flushes 
- (nightly) sweats 
Vacinal problems: 
- dryness 
- dyspareunia 
- pruritis 
- senile (colpitis 
Osteoporosis: risk 
- bone mass 1 SD 
Atypical complaints: 
- sleep disturbances 
- low self-confidence 
- palpitations 
- forgetfulness 
- concentration difficulties 
- paresthesia hands & feet 
- small-joint pain 
Urinary problems: 
- urge incontinence 
- stress incontinence 
- recurrent urinary infections 
profile: 
or more below mean of reference 
Cardiovascular disease: risk profile: 
- irritability 
- agitation 
- fatigue 
- melancholia 
- vertigo 
- headaches 
- anxiety 
population 
- current cardiovascular disease 
- risk factors: (familiary) hyperlipidaemia, diabetes mellitus, smoking 
habits, hypertension . 
References 19-30 
Atypical complaints are reported by many climacteric women, but are not 
necessarily related to the hormonal changes [31-33]. However, they may be the direct 
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consequence of hot flushes and sweats, and especially in the presence of the latter 
symptoms, they may respond well to oestrogen supplementation [10]. In the absence of 
hot flushes, atypical complaints may improve during oestrogen supplementation, but often 
to a lesser degree [10,34]. Some studies have demonstrated that oestrogens prolong 
R(apid) E(ye) M(ovement) sleep [35,36], and that sleep-disordered breathing periods are 
diminished [37]. Reportedly, women sleep longer during oestrogen supplementation [38]. 
In case of atypical complaints a probationary treatment of three months may help to find 
out or exclude the possible hormonal pathogenesis. 
Complaints of oestrogen deficiency, such as vaginal dryness, itching and 
dyspareunia, often respond well on local as well as systemic therapy. Also symptoms of 
genital prolapsus may improve [14,15,39-41]. Even with low-dose therapy the atrophic 
changes may disappear completely, and a short term treatment may give long lasting 
improvement. Urinary problems due to mucosal atrophy, such as dysuria, pollakisuria and 
recurrent cystitides, often accompany the vaginal symptoms. These symptoms may 
improve during oestrogen treatment [42,43], and if so one may continue its 
administration. Besides creams and suppositoria, there are new developments in the field 
of local treatment by a vaginal oestrogen releasing ring [44], and intravesical oestriol 
instillation [45]. 
Women reach their peak bone mass around 20 - 30 years (Figure 1). In women the 
mean peak bone mass is about 15% lower than in men. After this age, the balance 
between bone formation and bone resorption becomes slightly negative, leading to on 
average 0.5% to 1% loss of skeletal bone every year. After menopause bone turnover 
increases, however in such a degree that bone resorption exceeds bone formation, and 
results in about 18% more loss of trabecular bone and 12% more loss of cortical bone 
than in men within a relatively short time. The trabecular bone mass decreases about 1 to 
4% a year during the first 8 to 10 postmenopausal years [46-48]. 
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Bone mass 
10 20 30 40 50 60 70 80 90 
Age (yrs) 
Figure 1: Simplified illustration of bone mass as function of age and gender. 
(Adapted from: Barentsen R, 1989: Oestrogeen substitutie therapie. Waarom en hoe). 
Bone loss, as a result of ageing and menopause, may lead to osteopenia and 
osteoporosis. Postmenopausal osteoporotic fractures commonly concern the distal radius, 
vertebra and in the older women also the hip. Osteoporotic fractures, and especially hip 
fractures, are associated with a high morbidity and mortality rate [49-51]. 
Oestrogen replacement therapy is associated with decreased bone resorption and 
fracture risk [52-60]. Oestrogen supplementation for 5 years or more reduces the 
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osteoporotic fracture risk in the wrist and hip on the average with 50% [61-65], and 
vertebral fracture risk even more [66]. Several large scale studies have demonstrated the 
preventive effect on the incidence of osteoporotic fractures of hormones alone, and even 
more when combined with calcium supplements [67-69]. Oestrogens combined with a 
progestogen may to some extent even promote new bone formation [70,71]. Several 
factors, summarized in table Π, have been suggested to mediate the influence of sex 
steroids on the bone. 
Table II: Actions of sex steroids on bone 
Indirect effects Systemic factors: 
- Inhibition of insulin-like growth factor (IGF-I) 
- Increase in growth hormone 
Direct effects Increase of local growth factors: Steroid receptors: 
- Insulin-like growth factor (IGF-Π) - Oestrogen receptors 
- Transforming growth factor-B (TGF-ß) - Progesterone receptors 
- Binding proteins of IGF-I/-II, TGF-ft 
References 72-77 
The last decades an increasing amount of reports has demonstrated that hormone 
replacement therapy reduces the risk of developing cardiovascular disease in 
postmenopausal women. It will probably only be a matter of time that hormone 
supplementation will be accepted as an important treatment modality for primary and 
secundary prevention at least in postmenopausal women at risk for cardiovascular disease. 
This issue will be discussed in more detail in the paragraph "Cardiovascular impact of 
hormone replacement therapy". 
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CONTRA-INDICATIONS 
Although in most data-sheets on hormone supplementation many contra-indications 
are listed, it remains doubtful whether they are justified as they are not based on 
prospective scientific research. Many of the listed possible side-effects of low-dose natural 
oestrogen are the inheritance of the experiences with high-dose synthetic ethinyl-oestradiol 
containing oral contraceptives. Regrettably, it appears that natural oestrogen compounds 
as equine conjugated oestrogen and micronised 17B-oestradiol, are often considered 
similar to synthetic oestrogen, and it will need more effort to dissociate the former of this 
undesirable and unjustifiable reputation. 
Contra-indications [19-22] for administering hormone replacement are listed in 
table III. This section wil deal with the major objections for hormone replacement 
therapy. 
Table III: Contra-indications for hormone replacement therapy 
Contra-indications for oestropen: Contra-indications for propestopen: 
- Breast cancer - Meningeoma 
- Endometrial cancer 
- Severe liver dysfunction 
- Porphyrie disease 
References 19-22 
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Breast cancer 
Several conflicting reports have been published dealing with the effects of 
postmenopausal hormone treatment on the risk of developing breastcancer [78-94]. 
Although it still is a matter of debate, some of the latest reports have estimated a relative 
risk increasing with dose and duration of treatment. For long-term users (longer than 9 
years) some have estimated a relative risk up to 1.7 [95]. In a meta-analysis, Dupont et 
al. [96], however, have questioned these data. These authors found overall relative risk 
estimates of 1.07 and 1.08 in women taking conjugated oestrogen dosages of 0.625 mg 
per day or less, and 1.25 mg per day or more, respectively, so no clear dosage related 
effect was found. Supplementation of oestrogen shorter than five years does not seem to 
increase the relative risk at all. Grady et al. [20] also reported no clear evidence for an 
increased risk with increasing oestrogen dosages and different treatment regimen. They 
estimated a slightly increased relative risk of 1.25 for women who used oestrogen for 8 
years or more. Other possible variables concerning the risk of developing breast cancer 
are the type of oestrogen used, and the addition of a progestogen. Bergkvist et al. [95] 
reported a slightly increased risk for long-term users of oestradiol compounds, but not for 
users of conjugated oestrogen or other types of oestrogen. In addition, combined 
oestrogen-progestogen users showed no increased risk. 
It still remains questionable whether the estimated increases in relative risk 
reported are in part due to surveillance bias, since the hormone treated group may consist 
of highly motivated women that get more regular medical examination including 
mammographie surveillance. Therefore, breast cancer is earlier diagnosed in this group. 
An underestimation of the relative risk as a result of investigating women with low 
treatment compliance can, however, also not be excluded. Although breast cancer disease 
may be diagnosed in a slightly higher frequency during hormone replacement therapy, 
breast cancer mortality has not been found to be increased due to hormone 
supplementation [97]. Still, every woman, independent of hormone treatment, is prone to 
a relatively high life-time risk of 10% for getting breast cancer. For every woman the 
experience of having a possible breast disease, especially in the case of breast cancer, 
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may introduce severe emotional distress. Therefore, any sign of a possible breast 
abnormality needs to be investigated thoroughly, by breast examination as well as by 
mammography [98,99]. In case of an increased risk for breast cancer, with respect to risk 
factors as: familial history of breast cancer [99], premalignant abnormalities [100,101], or 
history of prenatal diethylstilbestrol exposure [102], mammographie surveillance once a 
year is recommended. In all other cases mammographie surveillance once every two years 
is considered efficacious. Furthermore, it has been recommended to perform a 
mammography before commencement of postmenopausal hormone treatment [22]. Women 
using hormone replacement therapy should be properly informed by their physician on the 
possible effects of hormones on the breast, and regular self-investigation should be 
promoted to improve the early diagnosis of breast disease. 
In women with a history of breast-cancer, hormone supplementation is considered 
contra-indicated. Oestrogens stimulate glandular tissue, especially in case of oestrogen 
and/or progestogen receptor presence. Therefore, growth of possible micro-metastases is 
considered a substantial risk. However, in some cases of extreme climacteric symptoms, 
hormone supplementation under good medical supervision may be justified in order to 
improve the quality of life [21,98,99]. 
Benign breast tumors as fibrocystic breast abnormalities are no risk factor for 
breast cancer, and therefore, are no contra-indication for hormone replacement therapy. 
About the non-carcinogenic effects of hormone treatment on fibrocystic abnormalities the 
literature is not consistent [103,104]. 
Endometrial cancer 
Endometrial hyperplasia and carcinoma may develop as a result of prolonged 
exposure to oestrogen stimulation of the endometrial cells [105]. The risk of developing 
endometrial neoplasia increases with the dose and the duration of the oestrogen 
administration [106-113]. Grady et al. [20] estimated a relative risk for ever users of 
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oestrogen of 2.31, while women who used oestrogen for 8 years or more showed a 
relative risk of 8.22. Furthermore, oestradiol has much stronger hyperplastic and 
carcinogenic effects than oestriol, which is often used for local treatment of urogenital 
problems. Some authors have reported that endometrial carcinoma due to prolonged 
oestrogen exposure shows a low malignancy grade, and has a better prognosis [114]. 
After total hysterectomy for endometrial cancer, oestrogen treatment is still considered 
contra-indicated, to prevent de novo stimulation of possible micro-metastases. However, 
some small studies have reported that in stage I endometrial carcinoma the risk of relaps 
is very low [115-118]. Therefore, if firm indications for oestrogen supplementation are 
present, it has been proposed that in these cases oestrogens may be prescribed, but then 
continuous combination with a progestogen should be given. In cases with history of 
endometrial carcinoma with high-grade malignancy and five years free of relapse, 
oestrogen supplementation combined with continuous progestogen administration may be 
considered [22]. 
Liver disease 
Liver adenoma is a very rare complication of oral contraceptive use [119], and is 
no contra-indication for hormone supplementation. Since oestrogens and progestogens are 
metabolised in the liver parenchyma, they must be considered contra-indicated in case of 
severely disturbed liver functions [22]. Little is known with respect to the effects of 
hormone supplementation in women with the rare Dubin-Johnson syndrome or the Roter 
syndrome. In such cases it is recommended to monitor the liver function during hormone 
supplementation [22]. 
Porphyrie disease 
Low-dose hormone treatment may disturb porphyrin metabolism [120,121]. Its 
implications for women with porphyria are still unknown, and therefore, cautiousness is 
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Meningeoma 
In meningeomas large amounts of progesterone receptors have been found [122-
126], and meningeomas have been reported to shrink during treatment with anti-
progestogens [127,128]. Therefore, until now meningeomas are considered as a relative 
contra-indication for progestogen administration, but there is no objection to unopposed 
oestrogens in this respect. However, recent studies [129-131] have questioned the 
significance of sex steroid influences on cerebral meningeomas. Further research may 
solve this controversy. 
Table IV lists some points that need special attention and extra care in women 
using hormone replacement therapy. When present, these problems may aggravate during 
hormone supplementation and therefore thorough follow-up is needed. As aggravation 
occurs treatment must be stopped. Some of the risks listed will be discussed below. 
Table IV: Problems that need special attention 
- Myoma uteri - Familiairy hypertriglyceridaemia 
- Endometriosis - Venous thrombo-embolic disorders 
- Migraine - Risk profile breast cancer: 
- Epilepsy - Family history 
- Gallstones - Premalignant abnormalities 
- Hypertension - History of diethylstilbestrol-use 
References 19-22 
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Gallstones 
Oral contraceptive use and hormone replacement therapy do increase the risk of 
gallstone disease and the chance of having a cholecystectomy {relative risk: 1.2 - 2.1) 
[132-136]. This effect has so far not been found during transdermal hormone replacement 
therapy [137]. In the presence of gallstones, but also in case of history of cholestatic 
jaundice, it is recommended to administer hormones in dosages as low as possible, or to 
choose for non-oral treatment [22]. The recurrence risk of gallstones after 
cholecystectomy is very low. 
Hypertension 
Hormone replacement therapy has been associated with a small percentage of 
idiosyncratic hypertension [138], the reason why control of blood pressure after three 
months of treatment is recommended. This observation, however, must not be considered 
an argument for withholding hypertensive women postmenopausal hormone treatment. 
Most studies have reported an unchanged blood pressure or even small decreases in 
systolic, and sometimes also in diastolic, blood pressure during hormone replacement 
therapy [139-142]. 
Venous thrombo-embolic disorders 
Although a history of venous thrombo-embolic disorders has been considered as 
contra-indication for hormone replacement, this statement has never been subscribed by 
clinical prospective studies. There is no clinical evidence that postmenopausal hormone 
replacement therapy increases the risk of thrombosis [143-145]. In women with history of 
spontaneous venous thrombosis, thrombosis during oral contraceptive use or during 
pregnancy, any deficiency of antithrombin III, protein-C or protein-S, must be excluded 
[22]. In women with one of these deficiencies, low-dose supplemention and good 
monitoring may be considered in case of severe climacteric complaints. Parenteral 
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administration may be more favourable than oral treatment, since it is reported to 
interfere less with liver metabolism, but no finn data are available to prove this. In case 
of thrombosis during hormone treatment it is recommended to stop the treatment, at least 
until adequate anti-thrombotic treatment is achieved [22]. 
CARDIOVASCULAR IMPACT OF HORMONE REPLACEMENT THERAPY 
Until menopause, women are relatively protected against cardiovascular disease, as 
compared to men. In the latter, the incidence of cardiovascular morbidity increases 
gradually with age, while in women cardiovascular disease incidence increases 
exponentially after menopause until a percentage almost as high as in men [146,147]. 
Consequently, the increase in cardiovascular morbidity and mortality is delayed in women 
until after menopause [148] (Figure 2). 
This phenomenon coincides with changes in the lipid profile, such as increases in 
the concentrations of total cholesterol, low-density lipoprotein cholesterol, and 
triglycerides, while those of high-density lipoprotein cholesterol decrease [149]. Opposite 
to the suggested more or less abrupt changes in cardiovascular morbidity and mortality, 
and in the lipid profile, some authors state that these variables show gradual changes in 
time, with no significant relationship with the hormonal changes in the climacteric [ISO]. 
In the last decades an increasing amount of data has been gathered on the 
relationship between cardiovascular disease and oestrogen use in postmenopausal women 
[146,151-183]. Reports uniformly point in the same direction: oestrogen replacement 
therapy decreases the risk of developing cardiovascular disease as much as 50% [172]. 
Table V and VI summarize some of these studies, and all except one (The Framingham 
Study [184,185]) demonstrate relative risk estimates lower than one. However, after re-
analysis of the latter data, the authors reversed their conclusion [169]. 
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Figure 2: Cardiovascular death rates related to age and gender. 
(Adapted from: US Department of Health and Human Services. Public Health Service. Centers 
for Disease Control. National Center for Health Statistics, 1988: Vital statistics of the United 
States 1986. Vol II: Mortality, part A. Hyatlsville, Maryland). 
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Table V: Effect of postmenopausal oestrogen replacement therapy on relative risk 
(RR) for cardiovascular disease in case-control studies 
Authors 
Rosenberg et al.1Я 
Talbotter α/.174 
Pfeffer et α/.153 
Rosenberg et al.175 
1976 
1977 
1978 
1980 
RR 
0.97 
0.34 
0.68 
1.00 
Authors 
Ross étal."5 
Baincra/.156 
Adamera/.157 
Szklo er af.158 
1981 
1981 
1981 
1984 
RR 
0.40 
0.70 
0.65 
0.61 
Table VI: Effect of postmenopausal oestrogen replacement therapy on relative risk 
(RR) for cardiovascular disease in prospective studies 
Authors 
Burchera/.159 
Gordon et a/.1*4 
Hammond et al. 16° 
Nachtigall et al.90 
Lafferty era/.162 
Wilson et al.™ 
Stampfer et al.™ 
1974 
1978 
1979 
1979 
1985 
1985 
1985 
RR 
0.40 
1.00 
0.33 
0.30 
0.17 
1.90 
0.30 
Authors 
Petitti etal.m 
Bush et al. '*' 
Hunt et a/.164 
Bush era/.180 
Criqui et al.1И 
Henderson et al.1B3 
1986 
1987 
1987 
1987 
1988 
1988 
RR 
0.50 
0.34 
0.50 
0.40 
0.79 
0.59 
Investigation of the differential effects in subgroups with and without history of 
cardiovascular risk factors, such as: overweight, low socio-economic class, hypertension, 
smoking habits, hyperlipidaemia and history of coronary infarction [186], revealed very 
interesting results. Risk reduction appeared stronger in women having a risk factor. 
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Women with angiographically defined coronary heart disease and treated with oestrogens 
showed the same ten-year survival as women without coronary stenosis; the diffference 
between oestrogen users and non-users increased with increasing coronary stenosis 
[176,177,187,188]. These results stress the need for hormone replacement therapy, 
especially in women with an increased cardiovascular risk profile. However, because 
most other studies mentioned above have methodological impairments, these conclusions 
need confirmation [189]. 
Most studies investigated the changes in cardiovascular risk during unopposed 
oestrogen treatment. Since Ziel & Finkle [109] reported an increased risk for endometrial 
cancer during unopposed oestrogen treatment in non-hysterectomized women, more 
studies demonstrated the risk for developing endometrial hyperplasia and endometrial 
carcinoma [105-107,110-113]. Administration of a progestogen, continuously or cyclical 
for 12 days or more per 28 day cycle, protects the endometrium for these hazards [105]. 
Combined oestrogen/progestogen treatment reduces the incidence of endometrial 
hyperplasia and carcinoma to frequencies even below those seen in untreated women 
[108]. In Europe the monthly cyclical administration of a progestogen is common 
practise. 
Until now many reports, not necessarily in postmenopausal women, have 
described possible unfavourable metabolic effects of progestogens, especially with respect 
to its influences on the lipid profile [190-193]. Since no direct data were available of 
progestogenic effects on cardiovascular disease, the results of these reports were 
extrapolated as that progestogens attenuate, or even reverse the cardiovascular protective 
effects exerted by oestrogen. Recently, some observational studies indicated that little 
difference exists between unopposed oestrogen and combined oestrogen/progestogen 
treatment with regard to the cardiovascular risk profile (Table П). These results can be 
criticized because they lack randomised controlled groups. To clear this, large 
epidemiological randomised controlled trials are at present ongoing in the United States. 
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Table VII: Effect of combined oestrogen/progestogen therapy on relative risk (RR) for 
cardiovascular disease 
Authors RR Authors RR 
Nachtigall et al.90 1979 0.3 Hunt et al.,a 1990 0.3 
Thompson er ai.194 1989 0.9 Falkebom et al.,67 1992 0.5 
MECHANISMS UNDERLYING THE HORMONE RELATED CHANGES 
IN CARDIOVASCULAR RISK 
The explanation of the reported oestrogen related reduction in cardiovascular 
morbidity and mortality with up to 50% has been subject of many studies. These 
investigations can be divided in two categories: studies on direct (cardiovascular effects 
and studies on non-direct effects, especially the metabolic studies. 
Direct (cardiovascular effects 
Oestrogens exert acute and long-term vasodilatator changes in coronary as well as 
periferal arterial vessels. They increase the blood flow through the brain and the heart 
[195]. The peripheral resistance is diminished [196,197], leading to lowered blood 
pressure, systolic as well as diastolic. Oestrogens have recently been described to have 
calcium-antagonistic effects on the vascular wall [198]. Furthermore, Rosano et al. [199] 
reported beneficial effects of sublingual oestrogens on the ECG during exercise-induced 
myocardial ischaemia in women with proven coronary artery disease. 
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Prostaglandins 
Prostacyclins have a vasodilatator^ effect, when released by the endothelial cells. 
17ß-Oestradiol has been reported to stimulate the prostacyclin release [200,201], and by 
this mechanism it may exert its vasorelaxing effect. 
Lipid profile 
Most studies investigating the changes in lipids and lipoproteins during oestrogen 
supplementation in postmenopausal women have found a decrease in the atherogenic 
factors total cholesterol and low-density lipoprotein cholesterol, while the triglycerides 
and the anti-atherogenic high-density lipoprotein cholesterol increase [161,202-210]. 
Commonly, triglycerides decrease when high-density lipoproteins increase, but during 
oestrogen supplementation triglycerides rise, even when high-density lipoproteins 
increase. However, the rise in triglycerides reflects the rise in very low-density 
lipoprotein triglycerides, and these have a very low atherogenicity [211,212]. So, most 
changes during oestrogen administration can be considered favourable with respect to the 
risk of developing cardiovascular disease. Since unopposed oestrogen has been found to 
increase the risk of endometrial carcinoma combined oestrogen/progestogen treatment is 
recommended in non-hysterectomised women. This has prompted research to investigate 
the progestogen related effects on the lipid profile. The first reports indicated 
unfavourable androgenic effects, more so by the C-19 progestogens than the C-21 
progestogens [190]. However, these effects also depend on the dosage, as well as the 
route and duration of administration of the progestogen [190-193,210]. In the recently 
developed low-dose C-19 progestogen containing preparations, the attenuation of the 
oestrogen induced beneficial changes in lipids and lipoproteins, if any, is comparable with 
those of the C-21 progestogens [213,214], especially during long-term treatment [215]. 
Until recently, changes in the conventional risk estimators as lipids and 
lipoproteins were considered the most important mechanism explaining the oestrogen 
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induced risk reduction in cardiovascular disease. However, recently, this mechanism has 
been stated only to explain up to 25% of the cardiovascular risk reduction [216]. In 
experimental animal studies, oestrogen and combined oestrogen/progestogen have been 
found to reduce atherosclerotic lesions in equal degree, even when serum lipoprotein 
concentrations were unchanged [217-222]. So, the reduction in cardiovascular disease 
seems to be the result of a conversion in the development of atherosclerosis, but this 
phenomenon can probably only in part be explained by the changes in the conventional 
risk estimators. This area is still open for further investigation to unravel other underlying 
mechanisms. However, the importance of lipids and lipoproteins as markers of metabolic 
changes must not be neglected. 
Another factor that is involved in atherosclerosis lies in the qualitative properties 
of low-density lipoproteins. Low-density lipoproteins in its native (non-modified) form 
have a relatively low atherogenetic impact, but after modification by oxidation it becomes 
highly atherogenetic by binding to peripheral "scavenger receptors" in the vascular wall, 
after which it excessively accumulates in macrophages, the precursors of "foam cells". 
Accumulation of lipids leads to fatty streak formation, and these are the basis for 
atherosclerotic lesions [223]. 
Low-density lipoproteins are a heterogenetic group of particles with a diversity of 
size, density, molecular mass and chemical composition [224,225]. Small low-density 
lipoprotein particles have been associated with coronary heart disease [226-232], but this 
has been found to be accompanied with low high-density lipoprotein and with elevated 
triglyceride levels. Furthermore, small low-density lipoprotein particles are more 
susceptible to oxidative modification than large particles, and this may explain their 
higher atherogenetic potency [233]. Research on hormonal effects on low-density 
lipoprotein particle size and oxidizability may help to elucidate a part of the other 75% of 
cardiovascular risk reduction during postmenopausal hormone replacement therapy. 
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Carbohydrate metabolism 
In postmenopausal women the pancreatic insulin secretion decreases, and the 
insulin fraction passing the liver increases. The insulin-resistance increases progressively 
after menopause. It has been reported that administration of oestradiol can attenuate this 
increased insulin-resistance, which phenomenon has not been demonstrated for other 
oestrogens [234]. These influences may possibly provide a mechanism contributing to the 
reduced cardiovascular risk during hormone replacement therapy. Moreover, it subscribes 
at least the opinion that women with diabetes mellitus, and therefore at risk for 
cardiovascular disease, rather benefit by oestrogens than the opposite. 
Homocysteine 
Homocysteine is the demethylated derivative of the essential amino acid 
methionine [235]. Its metabolic pathway is shown in Figure 3. 
Elevated blood concentrations of homocysteine are an established risk factor for 
premature vascular disease. The autosomal recessive inherited metabolic disease 
"homocystinuria" is caused by a cystathionine ß-synthase deficiency, and is characterized 
by massive urinary excretion of homocysteine and severe elevation of blood methionine 
and homocysteine. Premature atherosclerosis and thrombo-embolism are life-threatening 
complications of homocystinuria. This is explained by homocysteine-induced endothelial 
cell injury, which may initiate the development of typical atherosclerotic lesions [236]. 
Several studies have demonstrated that even mildly elevated blood concentrations of 
homocysteine (hyperhomocysteinaemia) are associated with an increased risk of vascular 
disease [237-241]. Furthermore, hyperhomocysteinaemia has also been reported as risk 
factor for recurrent early pregnancy loss [242], neural-tube defects [243], and possibly 
placental abruption [244]. 
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Figure 3: Simplified scheme of the methionine-homocysteine metabolism and 
enzymes and vitamines involved. (1) Cystathionine ß-synthase; (2) 5-
methyltetrahydrofolate-homocysteine methyltransferase; (3) 5,10-methylene-
tetrahydrofolate reductase. 
(Adapted from: Wouters MGAJ, et al., 1993: reference 242). 
There are several reports that blood homocysteine concentrations, determined as 
free disulfides, as well as total homocysteine, are higher in men as compared to women. 
Furthermore, some studies, though inconsistently, have demonstrated higher homocysteine 
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levels in postmenopausal women as compared to those in premenopausal women [245-
249]. Thus, homocysteine metabolism may indeed explain in part the difference in 
cardiovascular risk between pre- and postmenopausal women [246]. Until now, the role of 
homocysteine metabolism as a possible pathogenic mechanism mediating the hormone 
related changes in cardiovascular risk in the perimenopause as well as during hormone 
replacement therapy has only scarcely been investigated. 
BENEFIT / RISK - RATIO OF HORMONE REPLACEMENT THERAPY 
The increasing amount of epidemiological data on all aspects of hormone 
replacement therapy in postmenopausal women should help in the decision making by the 
general phycisian as well as the gynaecologist. For counseling the women in need for 
treatment of climacteric symptoms, knowledge of the latest epidemiological data is of 
course indispensable, although it may be hard to catch up with the growing amount of 
new data. 
In general terms there is no doubt that hormone replacement is effective for the 
relief of climacteric symptoms and complaints, and for treatment of urogenital problems. 
Possible contra-indications as described before, although infrequently present, must be 
eliminated by proper (family) history taking and by physical, gynaecological and 
mammographie examination. The goal must be to achieve the most effective treatment of 
symptoms of complaints with as little as possible adverse reactions and, in non-
hysterectomised women, as little as possible bleeds, by individualisation of the treatment. 
Women without symptoms still may need hormone replacement therapy for the 
prevention of postmenopausal osteoporotic fractures. Bone densitometric measurement, a 
very accurate risk estimate for the occurrence of future bone fractures [250,251], may 
help to decide whether hormone replacement therapy must be advised. In such cases 
hormone treatment can at best be started soon after menopause. It should be realized that 
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prevention of osteoporosis by hormone replacement therapy requires long-term treatment. 
At present many data indicate that hormone supplementation has a cardioprotective 
effect. Although tempting, at this moment it may be too premature to advocate oestrogen 
treatment as a new drug for the cardiologist. However, much would have been achieved 
when, in case of (suspected) cardiovascular disease or the presence of one or more risk 
factors, oestrogen treatment would no longer be abandoned. In the near future it can be 
expected that oestrogen administration will become a new treatment modality for 
postmenopausal women with (an increased risk of developing) cardiovascular disease. 
In conclusion, hormone replacement therapy may benefit many women in their 
peri- and postmenopausal years, and when the few contra-indications are excluded it is 
unlikely that this type of treatment will introduce new hazards. Furthermore, 
cardiovascular morbidity, or at least existing risk factors for developing cardiovascular 
disease may become new indications for hormone treatment, instead of being considered 
as an objection for it [252-259]. 
ROLE OF PROGESTOGENS 
As already mentioned before, the cyclic addition of a progestogen to the oestrogen 
is strongly recommended to prevent irregular bleeding episodes and the development of 
endometrial hyperplasia and ultimately endometrial cancer. However, cyclical 
oestrogen/progestogen regimen restore vaginal bleeding in 80% to 90% of women [260], 
and this may interfere with patient acceptance of the treatment [261-263] at an age when 
cessation of menses is anticipated. Progestogens are not believed to exert protective 
effects on all organ systems. For instance, progestogens may increase the mitotic index in 
breast tissue, although until now data on the progestogenic effects on the breast are 
inconsistent. The bone mass may benefit by combining oestrogen with a progestogen 
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[70,71], but also on this issue only few data are available. Progestogens may attenuate the 
oestrogen induced beneficial changes in the lipid profile. This depends on the type and the 
dosage of the progestogen, and on the route and the duration of its administration. 
Nevertheless, according to the latest reports, combining oestrogen with progestogens does 
not seem to alter the cardioprotective effects of oestrogen much. 
Although the importance of progestogen administration seems obvious with respect 
to the prevention of endometrial disease, its impact on the other organ systems is yet 
incompletely known. More research is necessarry to elucidate the differential effects 
introduced by the different combined oestrogen/progestogen treatment regimen [21]. 
COMPLIANCE AND ACCEPTANCE 
Most data on combined oestrogen/progestogen treatment concern a monthly 
sequential regimen. In most women sequential regimen, however, restore vaginal bleeds 
[260], and for many women this consequense of combined hormone treatment impairs the 
acceptance of the treatment [261-263]. Patient compliance after two years reportedly was 
less than 20% [264]. Considering the long-term preventive effects of hormone 
replacement therapy on osteoporosis and cardiovascular disease, these scores are 
disappointing, since most benefits can be expected when hormone treatment is started 
soon after menopause, and administered for a long period of time. Hormone 
supplementation for a shorter period, or starting the treatment later on after menopause, 
however, does not necessarily mean that the treatment is useless with respect to 
osteoporosis and cardiovascular disease prevention [64]. Consequently, to improve patient 
acceptance, more research is needed on different treatment regimen to determine their 
impact on the safety of the endometrium, the bleeding characteristics, patient acceptance 
and compliance. 
Recently, new developments in research are concentrating on the effects of 
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alternative treatment regimen, such as combined continuous oestrogen/progestogen 
administration [265-270] and prolonged treatment cycles [271,272]. Until now, the first 
data indicate that combined continuous treatments induce an atrofie endometrium and that 
withdrawal bleeds disappear. However, this condition is often established only after 
several months, during which period breakthrough bleeds may occur. Breakthrough 
bleeding may be associated with a hyperplastic endometrium, as well as with an atrophic 
endometrium. Therefore, these unexpected bleeds may introduce diagnostic difficulties. 
Until recently unexpected genital bleeds were investigated by dilation and curettage 
procedure. New developments as ultrasound [273,274] and endometrial biopsy [275] may 
in the near future simplify the diagnostic procedure. To avoid these diagnostic problems, 
it is at present advised to delay the administration of combined continuous treatment 
regimen until the women are postmenopausal for some time [21]. In this respect, 
however, six months as well as two years are recommended [21,276]. Before that 
moment, sequential regimen are prefered. Although little data are available on other 
regimen than the monthly sequential treatment, it appears that in general practise many 
physicians choose to prolong the treatment cycle to two or even three months of 
continuous oestrogen supplementation, combined with 10 - 14 days administration of a 
progestogen at the end of the treatment cycle. Reducing the incidence of withdrawal 
bleeds seems an interesting strategy to improve patient acceptance and compliance, but 
further research still has to support this hypothesis. 
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ABSTRACT 
Objective: To study the possible changes in reproductive hormones, sex hormone 
binding globulin, serum lipids and lipoproteins, lipoprotein(a) included, coagulation and 
plasma glucose in postmenopausal women treated with continuous 17ß-oestradiol and 
cyclic dydrogesterone for 14 days per 28 days treatment cycle. 
Design: Open longitudinal prospective study. 
Duration: Twelve 28 days treatment cycles. 
Setting: Gynaecological department of a university hospital. 
Subjects: Twenty-seven healthy non-hysterectomised postmenopausal women. 
Results: After treatment for six cycles serum concentrations of FSH and LH decreased 
significantly with 43.0% and 24.4%, respectively. Serum concentrations of oestradiol and 
oestrone increased significantly with 302% and 792%, respectively, and SHBG increased 
as well with 111% (P<0.01). Serum total cholesterol decreased with 9.0% (P<0.01). 
Serum VLDL-cholesterol did not change significantly. Serum LDL-cholesterol decreased 
with 16.3% (P<0.01) and HDL-cholesterol increased with 8.0% (P<0.01). This was 
accompanied with similar significant changes in the apolipoproteins: apolipoprotein A-I 
rose with 14.4% and apolipoprotein В decreased with 6.0%. Serum triglycerides and 
VLDL-triglycerides increased significantly with 14.4% and 17.9%, respectively. 
Lipoprotein(a) decreased with 17.5% (P<0.01). These results more or less sustained at 
cycle twelve of treatment. Serum concentrations of antithrombin ΙΠ and plasma glucose 
did not change. Fibrinogen decreased slightly but significantly below the initial value. 
Conclusions: This combination replacement therapy gives beneficial changes in lipid 
metabolism indicating a reduced risk of developing coronary heart disease without 
unfavourably changing coagulation and glucose metabolism. The expected beneficial 
changes with oestradiol alone are not counteracted by the intermittent addition of 
dydrogesterone. Therefore, this oestrogen/progestogen scheme can indeed be 
recommended for use in HRT. 
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INTRODUCTION 
Hormonal replacement therapy (HRT) for women with postmenopausal complaints 
has become of increasing interest during the last decades. Hot flushes, perspiration and 
vaginal dryness, and also many subjective complaints, diminish or disappear in a majority 
of women soon after starting HRT [1]. 
Slowing down the early postmenopausal osteoclastic activity by oestrogen 
supplementation is of great importance in the prevention of osteoporotic fractures. In 
women with low bone mass and approaching menopause HRT is recommended [2]. 
Several large studies show that oestrogen replacement therapy (ERT) also reduces 
cardiovascular morbidity and mortality risk by approximately 50 percent [3,4]. 
Postmenopausal women with manifest coronary heart disease (CHD) appear to have the 
largest benefit of HRT [5]. 
Next to vasodilatators effects oestrogens and progestogens also influence the 
serum concentrations of lipids and lipoproteins. Oestrogens have beneficial effects on 
plasma lipids by decreasing serum total cholesterol (TC) and low-density lipoprotein 
cholesterol (LDL-C) and increasing high-density lipoprotein cholesterol (HDL-C). 
Progestogens may have oppositional effects [6]. These effects of HRT appear to depend 
on the type and the dosage of oestrogen and progestogen, and the route and the duration 
of their administration [7]. 
The usual prescribed dosages of HRT restore serum oestradiol (E2) concentrations 
to values as found during the early follicular phase of the menstrual cycle. At these 
concentrations oestrogen use is not associated with thrombogenesis and glucose-
intolerance [8,9]. 
In the present report we describe the effects of treatment with continuous 
administration of micronised ΥΙΆ-Έ^ (Zumenon®) in combination with dydrogesterone 
(Duphaston®) [10] cyclic for 14 days per 28 days treatment cycle in healthy 
postmenopausal women. Dydrogesterone is an unique progestogen, exerting little if any 
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influence on serum lipids which is in marked contrast with many other progestogens. The 
effects of this treatment on reproductive hormones and sex hormone binding globulin 
(SHBG), serum lipids and lipoproteins, including lipoprotein(a) (Lp(a)), coagulation 
factors and glucose metabolism was followed for up to one year. 
SUBJECTS AND METHODS 
The study was approved by the ethical committee of our hospital on beforehand. 
Included were generally healthy non-hysterectomised postmenopausal women, aged 49 to 
59 years, who were recruted by advertisement in a local newspaper during the months 
January until May 1990. The women were amenorrhoeic for at least six months and were 
screened to have follicle-stimulating hormone (FSH) serum concentrations within the 
range, characteristic for the postmenopausal phase. Excluded were women using drugs 
affecting lipid metabolism or who used hormonal therapy for the previous two weeks. 
Before entering the study the purpose of the protocol had been explained and written 
informed consent was obtained. 
All women were treated with micronised Πη-Έ^ (Zumenon®), 2 mg daily, and 
with dydrogesterone (Duphaston®), 10 mg daily for the first half of each 28 days 
treatment cycle, both orally administered (Solvay-Duphar, Weesp, The Netherlands). 
Clinical examination, endometrial biopsy performed by micro-curettage (Vabra® 
endocurette, Farina Lanfranco, Venezia, Italia), and fasting venous blood sampling took 
place before study entry and on day 12, 13 or 14 of the combined 17ß-E2 and 
dydrogesterone intake of cycles 6 (± 1 cycle) and 12 (± 1 cycle) for the assessment of 
reproductive hormones and SHBG (cycle 12 excluded), serum lipids and lipoproteins, 
antithrombin III, fibrinogen and glucose. 
60 
17ß-Oestradiol - Dydrogesterone & Lipoproteins 
Previous to study entry assessment of liver enzymes (ALAT, ASAT and gamma 
GT) and mammography was performed. At cycle 4, additional assessment of antithrombin 
ΙΠ and fibrinogen was performed in order to diagnose a possible early deterioration in the 
coagulation system. 
Serum concentrations of LH and FSH were measured with specific 
immunoradiometric assays (Medgenix, Fleurus, Belgium) and have been described 
elsewhere [11]. Serum concentrations of Έ^ were measured with an in-house RIA [12] 
and serum concentrations of oestrone (Ej) were measured by oestrogen-specific dextran-
coated charcoal (DCC) radioimmunoassay described by Heineman [13]. Serum concen­
trations of SHBG were measured by a commercially available non-competitive liquid-
phase immunoradiometric assay (Farmos Diagnostica, Turku, Finland) described by 
Hammond et al. [14]. 
Very low-density lipoproteins (VLDL) were isolated within 5 days after blood 
sampling by ultracentrifugation at d = 1.006 g/ml using a Kontron TFT 45.6 rotor for 
sixteen hrs at 168000 χ g at 14°C in a Beekman L7-55 ultracentrifuge [15]. HDL-C in 
these sera was determined by the polyethylene glycol 6000 method [16]. For HDL-C the 
inter-assay coefficient of variation amounted to 2.3% (n = 20). Serum TC and 
triglycerides (TG) were measured by enzymatic methods using commercially available 
reagents (CHOD-PAP cholesterol reagent, cat. no. 237574, Boehringer Mannheim, 
Mannheim, FRG, and SERA-РАК TG cat. no. 6684, Miles, Italia). Both measurements 
were performed with a centrifugal analyser (Multistat III). Inter-assay coefficients of 
variation were 1.7% and 1.5%, respectively (n = 20). The accuracy checked for 
cholesterol against an Abell-Kendall method approved by the Centers for Disease Control 
(Atlanta, USA) was within 3% of target values. LDL-C was calculated by subtracting the 
cholesterol content in the d< 1.006 g/ml fraction and in the HDL-fraction from total 
serum cholesterol. Sera to be analysed for apolipoproteins were stored at -80*C until the 
end of the study. To minimize the imprecision all samples from the same subject were 
analysed in the same run in duplicate. Apolipoprotein (Apo) Α-I and В were measured by 
immunonephelometry [17,18]. Lp(a) was measured with a radioimmunoassay procedure 
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(Pharmacia, Uppsala, Sweden). In this method plasminogen up to a concentration of 5 g/1 
gives no measurable crossreactivity. The inter-assay coefficients of variation for single 
measurements of Apo Α-I and Apo В were 5.8% and 6.2%, respectively (n = 12), and 
for Lp(a): 6.6% (n = 20). 
Antithrombin III was measured with the chromogenic substrate S2238 (Kabi 
Diagnostica AB, Mölndal, Sweden) using a microtiter technique. The fibrinogen 
concentration was determined with a clotting test using а КС 10 coagulometer (Amelung) 
as described by Clauss [19]. The intra-assay and inter-assay variabilities for means of 
duplicate measurements were calculated from several pools of plasma and were, 
respectively, 3.0% and 5.2% in the case of antithrombin III, and were 3.9% and 4.5% in 
the case of fibrinogen (n=10). 
After screening, 27 healthy postmenopausal women were included in the study. 
Characteristics are given in Table I. One woman was incorrectly admitted to the study as 
the initial endometrial biopsy showed focal adenomatous hyperplasia. Therefore she was 
excluded. There were three drop outs due to several reasons. 
In six women the dydrogesterone dosage was increased from 10 to 20 mg because 
of repeated spotting or withdrawal bleeding before day ten of the combined ΠΆ-Έ^ and 
dydrogesterone intake [20]. In the case of one woman venous blood sampling took place 
by mistake on day nineteen instead of day twelve to fourteen of the combined Πη-Έ^ and 
dydrogesterone intake. Another woman missed dydrogesterone seven days in two cycles 
and fourteen days in one cycle, due to repeated hospitalisation because of total hip 
surgery, without further violation of the protocol. Excluding the obtained data from these 
eight women did not change our results significantly, the reason why analyses on data of 
27 women will be discussed. 
Statistical analysis on the data of 27 women was performed on an "intention-to-
treat" basis. The last visit carried forwards (LVCF) analysis was used because of one 
exclusion due to screening failure and three drop outs. Apolipoprotein analyses were per­
formed on data of 23 women (data on one screening failure and three drop outs were not 
available). In case of normal distribution (descriptive statistics) the Student's paired t test 
62 
17ß-Oestradiol - Dydrogesterone & Lipoproteins 
and the repeated measures analysis of variance (ANOVA) was used, in the other cases we 
used the Wilcoxon's signed-rank test and the Friedman's two-way ANOVA. P-values in 
tables are given for comparing data of cycle 6 and cycle 12 versus cycle 0. A P-value of 
0.05 or less is considered to be statistically significant. Statistical analyses were per-
formed with the Dyna-stat computer program (Dynamic Microsystems, Inc., Washington, 
D.C., Pittsburgh, PA, USA). 
Table I: Descriptive statistics3 before treatment (cycle 0) and at cycle 12 
Age 
Amenorrhea 
Body-mass index 
Blood pressure: systolic 
diastolic 
(years) 
(months) 
(kg/m2) 
(mmHg) 
(mmHg) 
cycle 0 
54.0 ± 3.6 
52.8 ± 38.9 
24.5 ± 2.8 
126 ± 15 
82 ± 7 
cycle 12 
24.5 ± 3.0 
134 ± 15 
84 ± 6 
Ζ* 
NS 
<0.01 
NS 
a
: mean ± SD (N=27); b : Student paired t test, verified with repeated measures ANOVA 
RESULTS 
Mean age was 54.0 years and the mean period of amenorrhoea was 52.8 months 
(Table I). Thirteen women had used HRT before with a mean wash out period of one 
year {range: 14 days - 4 years). Six women (=22%) had a wash out period ranging 
between 14 days and 3 months. Mean body-mass index was 24.5 kg/m2. The mean 
systolic blood pressure increased from 126 to 134 mmHg (P<0.01). Seven women 
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(=26%) were cigarette-smokers, only three of them (=11%) smoked five cigarettes or 
more per day. 
During the first six cycles mean serum concentrations of FSH and LH both 
decreased, respectively from 83 to 48 IU/1 and from 31 to 23 IU/1 (P<0.01) (Table II). 
The mean serum concentrations of Ej and Ej both increased, respectively from 145 to 
583 pmol/1 and from 261 to 2329 pmol/1 (P<0.01). Mean serum concentration of SHBG 
increased as well from 53 to 111 nmol/1 (P<0.01). 
Table II: Reproductive hormones and SHBG before treatment (cycle 0) and on day 
12, 13 or 14 of the combined 17ß-oestradiol and dydrogesterone intake of 
cycle 6a 
cycle 6 
48 ± 26 
23 ± 13 
583 ± 339 
2329 ± 1594 
111 ± 45 
¿> 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
FSH 
LH 
E2 
El 
SHBG 
(IU/1) 
(IU/1) 
(pmol/1) 
(pmol/1) 
(nmol/1) 
cycle 0 
83 ± 27 
31 ± 10 
145 ± 150 
261 ± 131 
53 ± 25 
a: mean ± SD (N=27); b: Wilcoxon signed-rank test; FSH: follicle stimulating 
hormone; LH: luteinizing hormone; Щ: oestradiol; Ej: oes tro ne; SHBG: sex hormone 
binding globulin. 
During the first six cycles mean serum TC decreased from 6.32 to 5.75 mmol/1 
(P<0.01) (Table III and Figure 1). Thereafter it slightly increased to 5.96 mmol/1 which 
is still below the initial value (P<0.01). 
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Figure 1: Mean serum concentrations of total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) in mmol/l 
before treatment (cycle 0) and on day 12, 13 or 14 of the combined 17fl-oestradiol 
and dydrogesterone intake of cycles 6 and 12 (N=27); *: P<0.01. 
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The changes in mean serum TC were reflected in the mean serum LDL-C concentration 
which decreased from 4.47 via 3.74 to 3.92 mmol/1 (P<0.01 versus the initial value). 
During the study period mean serum HDL-C increased from 1.50 to 1.66 mmol/1 
(P<0.01). Mean serum VLDL-C did not change significantly. During the study period 
mean serum TG increased from 1.25 to 1.42 mmol/1 (P<0.05), which is reflected in a 
rise in VLDL-TG from 0.67 via 0.79 to 0.73 mmol/1 (statistically significant with 
ANOVA). Mean serum Apo Α-I rose from 1417 to 1672 mg/1 (P<0.01) (Table III and 
Figure 2). Mean serum Apo В decreased from 1589 via 1494 to 1554 mg/1 (P>0.05 ver­
sus the initial value). In this study population the serum concentration of Lp(a) was highly 
skewed (skewness 2.48). During the study period mean serum Lp(a) decreased from 303 
to 239 mg/1 (P<0.01). The median serum concentration decreased from 76 via 67 to 71 
mg/1. Re-analysis of the logarithmic of serum Lp(a) (skewness 0.22) showed a decrease 
from 2.01 (SD=0.69) to 1.90 (SD=0.68) (P<0.001; Student's paired / test). There was 
no correlation between serum Lp(a) and serum concentrations of TC, HDL-C, LDL-C, 
VLDL-C, TG, Apo Α-I or B. The [TC]/[HDL-C] ratio decreased from 4.41 (SD = 1.41) 
via 3.74 (SD = 1.07) to 3.78 (SD=1.12) (P<0.01 versus the initial value). The recently 
introduced atherogenic index ATH-INDEX [21] ( = [TC - HDL-C]x[Apo B]/[Apo 
A]x[HDL-C]) decreased from 4.48 (SD=3.37) via 2.78 (SD = 1.99) to 2.88 (SD=2.09) 
(P<0.01 versus the initial value). 
Thrombolysis was estimated by means of serum antithrombin III, thrombogenesis 
by means of serum fibrinogen. During the study period there was no significant change in 
mean serum antithrombin ΠΙ (Table IV). Mean serum fibrinogen slightly increased in the 
first four cycles from 2364 to 2436 mg/1. Thereafter it decreased to 2245 mg/1 (P<0.05 
versus the initial value). 
Mean plasma glucose concentration decreased during the study period from 5.3 via 
5.0 to 5.1 mmol/1 (P>0.05 versus the initial value). 
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Figure 2: Mean serum concentrations of apolipoprotein Α-I (Apo Α-I), apolipoprotein В 
(Apo B) and lipoprotein(a) (Lp(a)) in mg/I before treatment (cycle 0) and on day 
12, 13 or 14 of the combined 17n-oestradiol and dydrogesterone intake of cycles 6 
and 12 (N=23); · : P<0.01. 
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Table TV: Antithrombin ΙΠ and fibrinogen before treatment (cycle 0) and on day 12, 
13 or 14 of the combined 176-oestradiol and dydrogesterone intake of 
cycles 4, 6 and 12a 
cycle 0 cycle 4 cycle 6 cycle 12 ƒ * Ac 
AT m (%) 97 ± 4 98 ± 4 97 ± 5 96 ± 5 NS NS 
Fibr (mg/1) 2364 ±446 2436 ± 537 2304 ± 482 2245 ± 514 <0.05 * 
a
: in mean ± SD (N=27); b : P-values versus cycle 0; Wilcoxon signed-rank test; 
*: statistical significance verified with Friedman's two-way ANOVA (Ac). 
AT ΠΙ: antithrombin III; Fibr: fibrinogen. 
DISCUSSION 
Our study population was selected by advertisement in stead of using an 
outpatients department population for the purpose of shortening the inclusion period. 
Although this may have caused some selection bias, it has the advantage of a more 
homogeneous group as far as seasonal influences are concerned. 
All women in this study experienced a satisfactory relief of symptoms and 
complaints on the given combination therapy, with preponderantly few side-effects well 
within acceptable limits. In six women (=22%) the dydrogesterone dosage had to be 
increased from 10 to 20 mg because of repeated spotting or withdrawal bleeding before 
day ten of the combined 17ß-E2 and dydrogesterone intake. This may indicate that the 
optimal dose of this drug is in between 10 and 20 mg daily. This increase did not change 
the obtained results significantly. 
Although serum FSH and LH concentrations did not reach premenopausal values 
after six cycles of HRT, serum Έ^ was increased to normal premenopausal values as seen 
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during the follicular phase of the menstrual cycle. A remarkable increase is observed in 
the Ej serum concentration due to conversion from E2 to Ej. We speculate that the good 
and stable results as far as relief of climacteric symptoms are concerned depend on this 
interconversion where Ej acts as substrate (buffer) for Ej. 
The observed metabolic changes are not likely to be exclusively due to seasonal 
changes, because the start and the end of the study were in the same season. The lipid 
and (apo)lipoprotein analyses show marked beneficial changes: during the first six cycles 
we observed a rise in HDL-C with 0.12 mmol/1 (8.0%, P<0.01) that after twelve cycles 
even was 0.16 mmol/1. An increase of HDL-C with 10 mg/dl (equivalent to 0.26 mmol/1) 
has been associated with a decrease in risk of CHD of as much as 50 percent [3], 
although recently the antiatherogenic role of an increase in HDL-C has been questioned 
[22]. LDL-C decreased at the same time with 16.3% (P<0.01). These changes were 
accompanied with similar changes in the apolipoproteins: Apo Α-I rose with 14.4% 
(P<0.01) and Apo В decreased with 6.0% (P<0.01). TC decreased with 9.0% 
(P<0.01). TG were elevated without clinical relevance. Hence the atherogenic indexes 
[TC]/[HDL-C] and the recently introduced ATH-INDEX [21] decreased significantly with 
15% and 38%, respectively. These results more or less sustained at cycle twelve of 
treatment. The ATH-INDEX shows the greatest decrease compared with the other 
atherogenic indexes, so we speculate that the ΑΊΉ-INDEX might be clinically useful in 
describing changes in lipid metabolism. 
The main purpose of this study was to investigate whether or not the expected 
beneficial changes in lipid metabolism with Ej alone sustain during intermittent intake of 
dydrogesterone. Studies have questioned the use of some progestogens in HRT for the 
reason of reversal of beneficial changes in lipid metabolism [7]. With intermittent 
dydrogesterone administration the expected beneficial effects on lipid metabolism do 
sustain. This confirms the similar observation reported by Siddle et al. [23]. Therefore 
this oestrogen/progestogen scheme can indeed be recommended for use in HRT. 
The predictive value of changes in Lp(a) metabolism is not all clear [24,25]. An 
association between elevated Lp(a) concentrations and CHD seems to be established, but 
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the basic pathophysiological mechanisms behind this are still poorly understood. Little is 
known about possible changes in Lp(a) during HRT. Only recently a significant decrease 
in Lp(a) was found during norethisterone treatment, 5 mg twice daily, in postmenopausal 
women [26]. As dydrogesterone has no androgenic properties, our findings suggest that 
the decrease in Lp(a) during norethisterone treatment must be a progestational effect, 
more than an androgenic effect of norethisterone. A possible role in thrombogenesis and 
atherogenesis seems established and, although until now unproven, a fall in Lp(a) is 
probably beneficial, but this still needs further investigation by clinical trials. As in other 
studies Lp(a) was highly skewed in our study population but despite this we observed a 
significant decrease of 17.5% after six cycles and of 21.1% after twelve cycles in the 
mean serum concentration, which was not correlated with any other change in lipids and 
(apo)lipoproteins. In the light of our knowledge concerning the role of Lp(a) in predicting 
atherosclerosis and thrombosis, the significant decrease during ій-Ъ^ - dydrogesterone 
therapy may be of great importance. 
Our analyses of antithrombin Ш and fibrinogen not only confirm the assumption 
that low dosage HRT does not increase thrombosis risk, but it even slightly points in the 
opposite direction by a small but significant reduction in fibrinogen after twelve cycles. 
CONCLUSIONS 
It is concluded that HRT with continuous micronised ХПй-Ъ^, 2 mg daily, in 
combination with dydrogesterone, 10 mg or more daily and cyclic for fourteen days 
during each 28 days treatment cycle gives beneficial changes in lipid metabolism, 
including Lp(a), indicating a reduced risk of developing CHD without unfavourably 
changing coagulation or glucose metabolism. The expected beneficial changes with Ъ^ 
alone are not counteracted by the intermittent addition of dydrogesterone. Therefore this 
oestrogen/progestogen scheme can indeed be recommended for use in HRT. 
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ABSTRACT 
Introduction: Postmenopausal hormone replacement therapy (HRT) has been described 
to reduce the risk of developing cardiovascular disease (CVD), which can be attributed at 
least in part to beneficial effects of oestrogens on serum lipoproteins. Little is known 
about a possible counteracting effect by the progestogen integrated in modem HRT 
regimen. 
Objective: To study the possible changes in serum lipids, lipoproteins and apolipopro-
teins during HRT with special emphasis on the possible progestational effect. 
Study Design: In an open-label longitudinal non-comparative study 23 healthy non-
hysterectomised postmenopausal women were treated with continuous micronized 17ß-
oestradiol, 2 mg daily, in combination with cyclic dydrogesterone, 10 mg daily, the first 
14 days of each 28-days treatment cycle. The women were followed for up to two years. 
Results: After two years serum total cholesterol and low-density lipoprotein cholesterol 
had decreased with 9.0% and 18%, respectively (P<0.01), while high-density lipoprotein 
cholesterol had increased with 13% (P<0.01). The latter change was accompanied with 
similar increases in apolipoprotein A-I ( + 16%; P<0.01) and A-H (+13%; /><0.01), 
while apolipoprotein В remained unchanged. Serum very low-density lipoprotein (VLDL) 
cholesterol and VLDL-triglycerides increased with 28% and 21%, respectively, the latter 
reflecting the slight increase in serum triglycerides with 21%. These values, however, 
remained within the normal range. Serum lipoprotein(a) decreased with 16% (P<0.01). 
All calculated atherogenic indices decreased (P<0.01) during the study period. Serum 
lipids and (apo)lipoproteins did not change after withdrawal of dydrogesterone for 14 days 
during the combination therapy in the last cycle studied. Serum fibrinogen decreased with 
8.4% (P<0.01) in the first 12 cycles, after which it increased to 13% above baseline 
value (P<0.01 vs. baseline). Antithrombin ГП did not change and plasma glucose 
decreased with 5.7%. 
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Conclusions: This HRT regimen induces, also when given for a longer period, 
beneficial changes in the lipid profile, without affecting important indicators of 
thrombosis. Also the glucose metabolism does not seem to be interfered with. Cyclic 
administration of dydrogesterone does not unfavourably affect serum lipids and 
(apo)lipoproteins when combined with 17ß-oestradiol supplementation. Therefore, this 
combination hormone regimen can be recommended for use in HRT. 
INTRODUCTION 
Oestrogen replacement therapy (ERT) repeatedly has been described to reduce the 
risk of developing cardiovascular disease (CVD). In literature the estimates of this 
important preventive effect of ERT on CVD have been reported up to 50% [1-4]. 
Changes in the lipid profile during oestrogen supplementation have been considered to 
partly explain this phenomenon [1,5,6]. In the treatment of climacteric complaints in non-
hysterectomised women the addition of a progestogen is generally accepted to prevent the 
development of endometrial hyperplasia and carcinoma [7]. Progestogens, however, may 
counteract the ERT induced beneficial changes in the lipid profile [8,9]. This may depend 
on the structure and the dosage of the progestogen, and the route and duration of its 
administration. 
Dydrogesterone has been described as a metabolic inert progestogen to have little 
or no effect on lipid metabolism [10-12]. Recently, we reported on the beneficial changes 
on serum lipids and (apo)lipoproteins during one year of supplementation with micronised 
17ß-oestradiol and cyclic administration of dydrogesterone [13]. Since studies investiga-
ting the changes in lipid metabolism within six to twelve months have often been 
criticized for their short duration, we here report the 2-year results of this hormone 
replacement therapy (HRT) regimen. In addition we studied the effects of withdrawal of 
dydrogesterone for 14 days on the course of serum lipids and (apo)lipoproteins. Further-
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more, some blood clotting parameters and fasting plasma glucose were evaluated to 
determine a possible increase in the risk of developing thombosis or a deterioration in 
glucose metabolism. 
SUBJECTS AND METHODS 
The study was approved by the ethical committee of our hospital on beforehand. 
Included were healthy non-hysterectomised postmenopausal women, aged 49 to 59 years, 
who were recruited by advertisement in a local newspaper during the months January to 
May 1990. All women suffered climacteric symptoms and complaints and were 
amenorrhoeic for at least six months. They were screened to have follicle-stimulating 
hormone concentrations within the range, characteristic for the postmenopausal phase. 
Excluded were women using drugs affecting lipid metabolism or who used hormonal 
therapy for the previous two weeks. Before entering the study the purpose of the protocol 
had been explained and written informed consent was obtained. The results presented here 
concern the data of 23 women. Characteristics of the study population are given in Table 
I. 
All women were treated with micronised 17ß-oestradiol (Zumenon®), 2 mg daily, 
and with dydrogesterone (Duphaston®), 10 mg daily for the first half of each 28-day s 
treatment cycle, both orally administered (Solvay-Duphar, Weesp, The Netherlands). 
Fasting venous blood sampling was performed before study entry and on day 12, 
13 or 14 of the combined 17ß-oestradiol - dydrogesterone intake of cycles 6 ( ± 1), 12(± 
1) and 24 (± 1). Blood sampling took place after a 12-hours fast. To evaluate the 
possible differences in serum lipids and (apo)lipoproteins between the combined 
oestradiol-dydrogesterone phase and the oestradiol-only phase extra blood was sampled on 
cycle day 26, 27 or 28 of cycle 23 or 24. 
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Table I: Characteristics3 of the study population before treatment (cycle 0) and at 
cycle 24 
cycle 0 cycle 24 / * 
Age (years) 54.3 ± 3.5 
Amenorrhea (months) 56 ± 4 0 
Body-mass index (kg/m2) 24.6 ± 2.5 24.7 ± 2.9 NS 
Blood pressure: systolic (mmHg) 1 2 6 ± 1 5 1 3 7 ± 1 6 <0.01 
diastolic (mmHg) 82 ± 7 84 ± 6 NS 
a: mean ± SD (N=23); b: Wilcoxon signed-rank test. 
The assay procedures for quantitation of reproductive hormones and sex hormone 
binding globulin (SHBG), lipids and (apo)lipoproteins, antithrombin ΠΙ and fibrinogen 
have been described previously [13]. To determine a possible change in the ratio of 
apolipoprotein (Apo) Α-Ι/Α-Π we measured Apo A-II at the end of the study. It was 
determined in the serum samples, stored at -80°C, by radial immunodiffusion, using a 
specific antiserum raised in rabbit against purified Apo A-II. The between-day coefficient 
of variation for control sera was 7.4%. All samples were measured in duplicate and were 
repeated if the duplicates differed more than 10%. 
Statistical analysis was performed on data of the 23 women who completed the 2-
year study period. Baseline values of the 4 women who did not complete the full 2-year 
study, for reasons reported earlier [13], were not different from the whole study 
population. All variables were analysed with the Wilcoxon signed-rank test. In order to 
adjust for multiple testing a P-value less than 0.01 was considered statistically significant. 
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RESULTS 
Clinical aspects of the treatment 
All women experienced a satisfactory subjective relief of symptoms and complaints 
during the given HRT regimen. This was the main reason that 19 of the 23 women (83%) 
who completed the study desired to continue the treatment after the 2-year study period. 
During the study period the mean systolic blood pressure increased slightly but remained 
within the normal range (Table I). 
The mean fasting plasma glucose concentration decreased (P<0.05) from 5.3 (SD: 
0.6) to 5.0 (SD: 0.4) mmol/1. 
Reproductive hormones and SHBG 
After six treatment cycles the mean serum concentrations of follicle stimulating 
hormone (FSH) and luteinizing hormone decreased significantly to one-half and two-third 
of the initial values, respectively (Table II). The mean 17ß-oestradiol concentration 
increased significantly almost five-fold to values seen in the follicular phase of the 
menstrual cycle. Furthermore, mean serum oestrone and SHBG increased significantly 
ten-fold and two-fold, respectively. 
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Table II: Reproductive hormones and SHBG before treatment (cycle 0) and on day 
12, 13 or 14 of the combined 17ß-oestradiol and dydrogesterone intake of 
cycle 6a 
cycle 0 cycle 24 / * 
42 ± 19 <0.01 
21 ± 12 <0.01 
658 ± 307 <0.01 
2689 ± 1443 <0.01 
122 ± 38 <0.01 
a: mean ± SD (N=23); b: Wilcoxon signed-rank test; FSH: follicle stimulating hormone; 
LH: luteinizing hormone; F^: oestradiol; Ej: oestrone; SHBG: sex hormone binding 
globulin. 
FSH 
LH 
E2 
El 
SHBG 
(IU/1) 
αυ/ΐ) 
(pmol/1) 
(pmol/1) 
(nmol/1) 
84 ± 26 
31 ± 10 
143 ± 155 
263 ± 128 
54 ± 26 
Lipids and (apo)lipoproteins 
After six cycles the mean serum concentration of low-density lipoprotein (LDL) 
cholesterol decreased significantly from 4.47 to 3.63 mmol/1, whereas mean high-density 
lipoprotein (HDL) cholesterol increased significantly from 1.49 to 1.63 mmol/1 (Table 
ΙΠ). The decrease in LDL cholesterol was reflected in the significant decrease in total 
cholesterol from 6.32 to 5.66 mmol/1. Similarly, these changes were accompanied by a 
decrease in mean Apo В (1589 to 1494 mg/1; P<0.01) and an increase in Apo A-I (1417 
to 1621 mg/1; P<0.01). Furthermore, Apo A-II rose from 395 to 423 mg/1 (P<0.05), 
resulting in no significant changes in the Apo Α-Ι/Α-Π ratio. Very low-density lipoprotein 
(VLDL) cholesterol did not change significantly. Serum triglycerides (TG) increased from 
1.27 to 1.48 mmol/1 (P<0.05), which could mostly be attributed to the rise in VLDL-TG 
(P<0.05). 
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Serum lipoprotein(a) (Lp(a)) was positively skewed (skewness: 2.48; kurtosis: 6.34; 
range: 15 - 1890 mg/1; see figure) and the mean decreased significantly from 303 to 250 
mg/1, whereas the median decreased from 76 to 67 mg/1. Furthermore, all atherogenic 
indices, including the recently introduced ATH-IND [14], decreased significantly. 
Comparing the serum lipid and (apo)lipoprotein concentrations of cycle 24 with cycle 12, 
no significant differences were found. However, after two years of treatment mean serum 
Apo В had returned to values not significantly different from the initial value, and mean 
Apo A-II had increased to 445 mg/1, which was significantly higher than baseline. 
Effects of withdrawal of dydrogesterone 
No significant differences were found comparing the serum lipid and 
(apo)lipoprotein concentrations of the oestradiol-only phase (cycle day 26, 27 or 28) with 
the combined oestradiol - dydrogesterone phase (cycle day 12, 13 or 14) of cycle 23 or 
24. 
Blood clotting parameters 
During the 2-year study period the mean serum concentration of antithrombin III 
remained unchanged, whereas mean serum fibrinogen initially decreased significantly 
from 2367 to 2169 mg/1 during the first year, after which it increased slightly though 
significantly to 2666 mg/1 (Table IV). 
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LIPOPROTEIN^) 
<mg/l) 
1000 
100 
Figure: Serum concentrations of lipoprotein(a) in mg/1 {semi-loganthnuc scale) of all 23 
women before treatment (cycle 0) and on day 12, 13 or 14 of the combined 170-
oestradiol and dydrogesterone intake of cycles 6, 12 and 24. 
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Table IV: Serum concentrations of antithrombin ΙΠ and fibrinogen before treatment 
(cycle 0) and on day 12, 13 or 14 of the combined 176-oestradioI and 
dydrogesterone intake of cycles 4, 6, 12 and 24a 
Antithrombin ΠΙ (%) F* Fibrinogen (mg/l) f*> 
cycle 0 96.4 ± 4.4 2367 ± 463 
cycle 4 97.2 ± 3.7 NS 2382 ± 443 NS 
cycle 6 96.2 ± 5.6 NS 2239 ± 340 NS 
cycle 12 95.6 ±5.5 NS 2169 ± 378 <0.01 
cycle 24 95.0 ± 6.3 NS 2666 ± 533 <0.01 
a
: mean ± SD (N=23); b : /"-values versus cycle 0; Wilcoxon signed-rank test. 
DISCUSSION 
Only in two studies [11,12] the effects of a HRT regimen with dydrogesterone on 
the serum lipid and lipoprotein concentrations have been described. However, none 
reported on a study interval of two years. During HRT in healthy postmenopausal women 
with 17ß-oestradiol and cyclic dydrogesterone we found favourable changes in all serum 
lipids and (apo)lipoproteins measured. This favourable effect was reached within six 
months of treatment already, indicating that within six months a new and consistent 
"metabolic equilibrium" has developed. Studies on changes in lipid metabolism of six to 
twelve months have often been criticized for their short duration, but from our 
observation this seems unjustified. 
In the present study the changes in the Apo A-I/A-II ratio were used as an 
indicator for those in the HDL2/HDL3 ratio. Since no changes occurred we assume that 
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the used HRT regimen did not influence the HDL subfraction distribution. 
This HRT regimen appeared effective in decreasing the Lp(a) concentration, which 
can be considered as an independent risk factor for CVD [15-18]. Until now only 
nicotinic acid reportedly has an Lp(a) decreasing effect [19]. Earlier, postmenopausal 
ERT for six months showed a substantial, though insignificant, decrease in the mean 
Lp(a) concentration with 32% [18]. The insignificance in this decrease, however, may be 
attributable to the small population studied and to the large inter-individual variations of 
this parameter measured. In our study there was, irrespective of the pretreatment Lp(a) 
concentration, a gradual decreasing trend in the Lp(a) values during 24 cycles of 
treatment. This is in contrast to the observation of Lobo et al. [18]. In our study HRT 
was also found to be effective in women with high Lp(a) concentrations being the most at 
risk for developing CVD. Seven (30%) women had Lp(a) concentrations higher than 300 
mg/1, which increased their CVD risk about two-fold. Consistent with a 47% decrease of 
Lp(a) observed during postmenopausal administration of norethisterone, 10 mg daily [20], 
we found a 16% decrease of Lp(a) in our study population. Our study provides additional 
evidence that the decrease in CVD risk during postmenopausal HRT may result in part 
from the significant decrease in the serum Lp(a) concentrations, and that especially 
women with increased CVD risk with respect to their Lp(a) concentration may benefit the 
most of HRT. 
Furthermore, no significant differences were observed between the oestradiol-only 
phase and the combined oestradiol-dydrogesterone phase of cycle 23 or 24, which 
confirms our earlier suggestion [13] that dydrogesterone does not attenuate the beneficial 
changes during oestradiol-only therapy. 
During the first year of treatment serum fibrinogen decreased with 8.4% to values 
significantly lower than baseline (P<0.01). Thereafter, it increased with 13% to values 
significantly higher than baseline during the second year (P<0.01 vs baseline). All 
values, however, remained low normal {normal range: 2 to 4 g/t). As these values were 
determined in the daily routine haematology laboratory, we consider these fluctuations as 
the extremes in the analytical variation which amounted to 8%. Since high levels of Lp(a) 
86 
17ß-Oestradiol - Dydrogesterone & Lipoproteins 
have been demonstrated to nave antifibrinolytic effects [15,21] the observed Lp(a) 
decrease adds to the conclusion based on the other thrombosis parameters studied, that the 
specific HRT regimen used has not increased thrombosis risk. 
The systolic blood pressure was found to be slightly increased after two years of 
HRT, but stayed well within the normal range. No good explanation can be given for this 
change. However, since the diastolic blood pressure did not change, we may conclude 
that this slight change does not have any clinical relevance. 
It is concluded that HRT with continuous 17ß-oestradiol, 2 mg daily, and cyclic 
dydrogesterone, 10 mg daily, given the first half of each 28-days treatment cycle results 
in substantial changes in the serum lipids and (apo)lipoproteins, Lp(a) included. All these 
changes suggest a decreased risk for the development of CVD. The alterations can 
already be observed after a treatment of six months and are maintained for at least two 
years. In addition, dydrogesterone did not counteract the beneficial changes in serum 
lipids and (apo)lipoproteins observed during 17ß-oestradiol alone. 
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ABSTRACT 
Objective: To study the possible changes in serum lipids and (apo)lipoproteins during 
hormone replacement therapy with special emphasis on the possible additional effects 
brought about by the progestogen. 
Design: Open-label randomised prospective comparative study. 
Setting: Gynaecological outpatient department of a university hospital. 
Patients: Thirty-three healthy hysterectomised postmenopausal women. 
Interventions: Continuous oral supplementation with conjugated oestrogens, 0.625 mg 
daily, was administered either alone (group I; N = 18) or in combination with cyclic 
medrogestone, 5 mg daily during the last 12 days of each 28 days treatment cycle (group 
II; N = 15). 
Main Outcome Measure: Changes in serum lipids, lipoproteins and apolipoproteins 
after three, six and thirteen treatment cycles. 
Results: After one year of treatment significant increases were observed in mean 
concentrations of high-density lipoprotein (HDL) cholesterol, its subfractions, and 
apolipoprotein Α-I in group I and II: HDL cholesterol: +25.2% and +12.1%, 
respectively; HDL2 cholesterol: +47.4% and +23.5%, respectively; HDL3 cholesterol: 
+ 18.1% and +11.2%, respectively; apolipoprotein A-I: +23.0 and +14.8%, 
respectively. Comparing the two study groups no significant differences were found in 
lipid changes during the study period, except for HDL2 cholesterol. 
Conclusion: Supplementation with conjugated oestrogens, with and without 
medrogestone, and given for a longer period, demonstrated a beneficial influence on 
serum lipoproteins with almost no differences between the two treatment regimen. 
92 
Conjugated Oestrogen - Medrogestone & Lipoproteins 
INTRODUCTION 
Oestrogen replacement therapy reduces the risk of developing coronary heart 
disease in postmenopausal women [1-3]. This can be partly attributed to the beneficial 
changes in lipid metabolism. Especially a rise in high-density lipoprotein (HDL) 
cholesterol is considered as a beneficial change, whereas an increase in low-density 
lipoprotein (LDL) cholesterol indicates an increased risk of developing coronary heart 
disease [4,5]. In non-hysterectomised women it is recommended to combine oestrogen 
replacement therapy with a progestogen for prevention of hyperplasia and carcinoma of 
the endometrium. However, some progestogens may offset the effects of oestrogens, 
depending on the type and the dosage of the progestogen and the route and duration of its 
administration. Medrogestone is a derivative of 17a-hydroxy-progesterone of which only 
few studies exist concerning its effects on lipid metabolism [6-8]. 
The purpose of this randomised prospective study was to investigate the effects on 
lipid metabolism of continuous oral supplementation with conjugated oestrogens in 
combination with cyclic oral administration of medrogestone. Changes in the 
concentrations of serum lipids, lipoproteins and apolipoproteins were followed up to one 
year and were compared with a control group, receiving conjugated oestrogens only. 
SUBJECTS AND METHODS 
Sample size, necessary to detect a 20% difference in HDL cholesterol 
concentration between both study groups, with 80% power using a two-sided test at the 
5% significance level, was estimated at 16 women per study group. Volunteers were 
recruited by advertisement in a local newspaper during the months June to November 
1990. Thirty-five healthy hysterectomised postmenopausal women were selected with a 
serum FSH concentration greater than 40 IU/1 and a serum oestradiol (Ej) concentration 
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lower than 150 pmol/1. Excluded were women with history or active presence of 
thrombo-embolic disorders, cerebrovascular accident or ischaemic heart disease, chronic 
renal or hepatic disease, and known or suspected oestrogen-dependent neoplasia. Also 
excluded were women with gallbladder disease, neuro-ocular disorders, known 
hypersensitivity to oestrogens and/or progestogens and use of oral oestrogen or 
progestogen containing medication within three months prior to the prestudy screening. 
Also not included were women with blood pressure higher than 160/90 mmHg, liver 
disease, or with endocrine diseases, malabsorbtion disorders, any malignancy and cervical 
Papanicolaou smear of Class ΙΠ or greater (in case of supra-vaginal hysterectomy). 
Women smoking more than 15 cigarettes a day, with obesity, known alcohol or drug 
abuse and with any evidence of premalignant or malignant changes in the prestudy 
mammogram were also not included. During the study period chronic steroid medication, 
oestrogens or progestogens other than the study medication, and lipid lowering agents 
were not permitted. Baseline serum total cholesterol and triglyceride levels had to be 
respectively 6.7 mmol/1 and 2.8 mmol/1 or lower. 
The study was approved by the ethical committee of our hospital on beforehand. 
Before entering the study the purpose of the protocol had been explained and written 
informed consent was obtained. 
Physical examination and fasting venous blood sampling were performed at 
prestudy screening and between day 22-28 of the 28 days cyclic treatment regimen of 
cycles three, six and thirteen. Mammography was carried out at prestudy screening and 
cycle thirteen. Fasting venous blood sampling for lipid baseline values was repeated at 
least one week after prestudy screening, but prior to starting the treatment regimen. 
Venous blood sampling was performed after a minimum 12 hours fast. Laboratory safety 
screening (hematology, blood chemistry and routine urinalysis) was done at prestudy 
screening and at cycles six and thirteen. 
Serum concentrations of FSH were measured with a specific immunoradiometric 
assay (Medgenix, Fleurus, Belgium) which has been described elsewhere [9]. The intra-
assay and inter-assay variablities for means of duplicate measurements were calculated 
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from several pools of serum and ranged between 1.8-3.6% and 6.8-8.2%, respectively. 
Serum concentrations of ^ were measured with an in-house radioimmunoassay as 
described elsewhere [10]. The intra-assay and inter-assay variabilities for means of 
duplicate measurements were respectively 4.3% and 7.9%. 
Serum lipid and lipoprotein levels were determined by standard laboratory 
procedures. Serum total cholesterol and triglycerides were measured by enzymatic 
methods using commercially available reagents (CHOD-PAP cholesterol reagent, cat. no. 
236691, and GPO-PAP triglycerides reagent, cat. no. 701904, Boehringer Mannheim, 
Mannheim, FRG). HDL cholesterol in serum was determined by using the precipitation 
method with sodium phosphotungstate-Mg2+ [11] and LDL cholesterol was calculated 
with the Friedewald-formula [12]. Serum lipoproteins were isolated by density gradient 
ultracentrifugation [13] using a SW-40 Ti rotor for 18 hours 40,000 r.p.m. at 4 e C. 
Afterwards the top fraction (about 1.5 ml), containing very low-density lipoprotein was 
collected with a Pasteur pipette. The gradient was then fractionated into 40 fractions of 
250 microliter each using a capillary placed on the bottom of the tube attached to a 
micropump and a fractioncollector. Cholesterol was measured in each fraction using an 
enzymatic method (CHOD-PAP, Boehringer Mannheim, Mannheim, FRG). To find the 
precise position of the density gradient along the lipoprotein pattern (1.210 - 1.063 kg/1) 
and the cut-off point around and between HDL2 cholesterol and HDL3 cholesterol (1.125 
kg/1) the density of ten fractions was measured with a DMA 602 M densitometer (Mettler 
Paar, Austria) in each gradient. The volume of each fraction was calculated from its 
weight and density. Small differences between total HDL cholesterol and the sum of 
HDL2 cholesterol and HDL3 cholesterol could occur because any cholesterol in the very 
high-density lipoprotein fraction with a density higher than 1.210 kg/1 was not measured. 
Apolipoprotein Α-I and apolipoprotein В were determined by rate-nephelometry using 
polyvalent monospecific anti-apolipoprotein Α-I and anti-apolipoprotein В antiserum in a 
Beekman Array Protein System [14]. The intra- and inter-assay coefficients of variation 
were 5% and 8%, respectively. 
We selected 35 women who were in chronological order and at random allocated 
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to one of the two study groups by using a computerized randomisation list. Group I, 
containing 18 women, was treated with conjugated oestrogens, 0.625 mg (Premarin®) 
daily continuously. Group II, containing 17 women, was treated with conjugated 
oestrogens, 0.625 mg daily continuously, in combination with cyclic medrogestone, 5 mg 
(Colpro®) daily, given the last 12 days of each 28 days treatment cycle (Wyeth 
Laboratories, Hoofddorp, The Netherlands). 
There were five drop outs, two in group I and three in group Π. In group I one 
woman stopped the medication in treatment cycle four because of progressive nausea. The 
second one had to stop the medication in treatment cycle eight because a haemangioma of 
the liver was diagnosed by sonography that was performed in order to explain severe 
atypical epigastric pain. In group II one woman suffered from painful varicosis of the left 
calf and stopped the medication in treatment cycle two. The second one discontinued the 
medication in treatment cycle three because of vertigo during the medrogestone intake and 
finally the last woman had to stop the medication in treatment cycle ten because of 
symptomatic cholelithiasis. 
Statistical analysis: Lipid baseline values were calculated by averaging the 
screening value and the value obtained at least one week later. End point analyses were 
performed on the data of 33 women after excluding two women (group II) who dropped 
out before lipid assays in cycle three could have been performed. The last visit carried 
forward (LVCF) procedure was used in the case of the other three drop outs (two women 
in group I and one woman in group II). Since almost all variables were normally 
distributed (tested by skewness and kurtosis), statistical significance of within-group 
changes and between-group differences was tested with the repeated measures analysis of 
variance (ANOVA, two-factor analysis). For analysis of separate within-group changes 
we used the Student paired t test and for between-group differences (in descriptive 
statistics) the Student unpaired t test was applied. Variables are given as means + 
standard deviation (SD). A P-value lower than 0.05 was considered to be statistically 
significant. Statistical analyses were performed with the Dyna-stat computer program 
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(Dynamic Microsystems, Inc., Washington, D.C., Pittsburgh, PA, USA). 
RESULTS 
Characteristics of the two study groups are given in Table I. There were no 
statistically significant differences between the groups with regard to age at study entry, 
age at hysterectomy, wash out period, serum concentrations of FSH and E2, body-mass 
index (BMI) and blood pressure. 
Table I: Characteristics of the study groups3 
Group I Group II J* 
Age 
HE-agec 
Wash-out 
FSH 
Oestradiol 
BMI 
Blood pressure: 
- systolic 
- diastolic 
(years) 
(years) 
(months) 
(ГОЛ) 
(pmol/1) 
(kg/m2) 
(mmHg) 
(mmHg) 
53.1 ± 2.4 
41.8 ± 6.0 
15.5 ± 2.1 d 
87 ± 17 
100 ± 2 0 
25.1 ± 2.4 
128 ± 18 
83 ± 8 
(50-59) 
(30-51) 
(3.5-60) 
(50-120) 
(75-140) 
(20.4-28.3) 
(100-155) 
(60-90) 
54.6 ± 3.3 
43.3 ± 3.3 
33.0 ± 48.9е 
87 ± 3 0 
92 ± 19 
25.3 ± 1.2 
135 ± 13 
83 ± 6 
(50-59) 
(36^7) 
(5-120) 
(43-140) 
(75-120) 
(23.5-27.9) 
(110-160) 
(70-90) 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Group I (N=18): conjugated oestrogens 0.625 mg only; Group II (N=15): conjugated oestrogens 
0.625 mg and cyclic medrogestone 5 mg on days 17-28 of the 28 days treatment regimen. 
a
: values are means ± SD (range); b : Student unpaired t test for between-group differences; c : age 
at hysterectomy; d : N = 10; e: N=5. 
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In group II we found a temporary decrease in the mean systolic blood pressure to 
127 ± 8 mmHg (P<0.05 vs baseline) during cycle six that returned to the baseline value 
at cycle thirteen. 
During the hormone therapy all women experienced a satisfactory relief of 
climacteric and postmenopausal complaints and symptoms. Twenty-three of the 30 women 
(77%) who completed the study desired to continue the oestrogen replacement therapy. Of 
the five drop outs the nausea and vertigo in two patients may obviously be a result of the 
given medication, whereas we can not exclude that the other diagnosed reasons for drop 
out were present already at study entry. 
Comparing the two study groups no significant differences were found in lipid 
changes during the study period, except for HDL2 cholesterol (P<0.05; Table Π). After 
three cycles serum total cholesterol initially decreased in both groups (group I: 2.2%, 
P>0.05; group II: 6.7%, P<0.05) after which there was a rise resulting in 
concentrations not significantly different from baseline values. Furthermore, the serum 
concentrations of very low-density lipoprotein cholesterol tended to increase, but this was 
not found statistically significant. During the first three cycles serum concentrations of 
LDL cholesterol decreased significantly (P<0.01), with 11.2% and 13.7% in group I and 
II, respectively. In group I this was followed by a rise during the course of the study to 
values that were not significantly different from baseline values whereas in group II the 
decrease sustained. This difference between the treatment groups did not reach statistical 
significance. HDL cholesterol serum concentrations rose significantly in both groups 
(P<0.01) , but the most (25.2%) in group I (Figure 1). The cholesterol values along the 
density-gradient between 1.210 and 1.063 kg/1 (about 30 fractions) revealed a bimodal 
distribution in most patients reflecting HDL·) cholesterol (the lesser dense subclass) and 
HDL3 cholesterol. The determination of the two subclasses was based on calculation of 
the area under the curve. The recovery was 99.7 ± 5 % . 
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Table II: 
TC° 
VLDL-C0 
LDL-C0 
HDL-C0 
HDLj-C0 
HDL3-C0 
TGC 
VLDL-TGC 
Apo A-Id 
ApoB d 
Π 
I 
II 
I 
π 
I 
II 
I 
II 
I 
II 
I 
II 
. I 
II 
I 
π 
I 
II 
Serum concentrations of lipids 
baseline 
5.86 ± 0.75 
6.29 ± 0.56 
0.57 ± 0.22 
0.74 ± 0.21 
3.84 ± 0 . 6 6 
4.10 ± 0 . 5 0 
1.39 ± 0.28 
1.40 ±0.28 
0.38 ±0.15 
0.34 ±0.13 
0.94 ±0.16 
0.98 ±0.19 
1.26 ±0.42 
1.58 ±0.46 
0.57 ± 0.28 
0.81 ± 0.35 
152 ± 20 
155 ± 24 
134 ± 24 
148 ± 18 
cycle 3 
5.73 ± 0.73 
5.87 ± 0.49* 
0.66 ± 0.33 
0.74 ± 0.29 
3.41 ± 0.76* 
3.54 ± 0.46* 
1.67 ± 0.36* 
1.58 ±0.31* 
0.59 ± 0.24* 
0.51 ±0.21* 
1.01 ±0.17* 
1.01 ±0.17 
1.52 ±0.78* 
1.71 ±0.68 
0.73 ± 0.54 
0.83 ± 0.45 ' 
179 ± 22* 
179 ± 23* 
129 ± 25 
138 ± 23* 
and (apo)lipoproteins in group I and IIa 
cycle 6 
5.83 ± 0.75 
5.87 ± 0.75* 
0.63 ± 0.29 
0.77 ± 0.37 
3.51 ± 0.77* 
3.56 ± 0.68* 
1.69 ± 0.41* 
1.55 ±0.31* 
0.60 ± 0.29* 
0.42 ±0.16* 
1.03 ±0.17* 
1.06 ±0.21* 
1.59 ±0.77* 
1.79 ±0.75 
0.71 ± 0.46 
0.80 ± 0.48 
179 ± 24* 
176 ± 25* 
130 ± 27 
141 ± 30 
cycle 13 
6.08 ± 0.89*-s 
5.90 ± 0.80* 
0.70 ± 0.36 
0.71 ± 0.36 
3.65 ± 0.81 
3.60 ± 0.64* 
1.74 ±0.42* 
1.57 ±0.35* 
0.56 ± 0.26* 
0.42 ±0.19* 
1.11 ±0.23* 
1.09 ±0.23* 
1.54 ±0.73* 
1.77 ±0.86 
0.75 ± 0.49* 
0.89 ± 0.59 
187 ± 32* 
178 ± 27* 
136 ± 27 
140 ± 30 
AN* 
# 
NS 
$ 
$ 
$ 
$ 
# 
NS 
$ 
NS 
rANB 
* 
NS 
NS 
* 
# 
NS 
NS 
NS 
NS 
NS 
Group I (N = 18): conjugated oestrogens 0.625 mg only; Group II (N = 15): conjugated oestrogens 
0.625 mg and cyclic medrogestone 5 mg on days 17-28 of the 28 days treatment regimen. 
a
: values are means ± SD; concentrations in c : mmol/1 and . mg/dl; statistics by . Student 
paired / test (differences versus baseline) and ANOVA (ANW: within-group changes; ANB: 
between-group differences); *: 0.05 ¿P<0 .1 ; #: P<0.05; $: P<0.01 ; TC: total cholesterol; 
VLDL-C: very low-density lipoprotein chol; LDL-C: low-density lipoprotein chol; HDL-C: high-
density lipoprotein chol; гШЦ-С: high-density lipoprotein chol; HDL3-C: high-density 
lipoprotein chol; TG: triglycerides; VLDL-TG: very low-density lipoprotein TG; Apo A-I: 
apolipoprotein Α-I; Apo B: apolipoprotein B. 
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О 
0 3 6 
cycle 
13 
Figure 1: Serum concentrations of total HDL cholesterol (HDL) and its subfractions HDL2 
(HDL2) and HDL3 (HDL3) cholesterol in mean ± SD at baseline (cycle 0) and on 
day 22-28 of treatment cycle 3, 6 and 13. Group I (N=18; open symbols): 
conjugated oestrogens 0.625 mg only; Group Π (N=15; filled symbols): 
conjugated oestrogens 0.625 mg and cyclic medrogestone 5 mg on days 17-28 of 
the 28 days treatment regimen. 
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Figure 2: Serum concentrations of apolipoprotein Α-I (Apo A) in mean ± SD at baseline 
(cycle 0) and on day 22-28 of treatment cycle 3, 6 and 13. Group I (N=18; open 
symbols): conjugated oestrogens 0.625 mg only; Group Π (N=15; filled symbols): 
conjugated oestrogens 0.625 mg and cyclic medrogestone 5 mg on days 17-28 of 
the 28 days treatment regimen. 
cycle 
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During the first three cycles serum concentrations of HDL2 cholesterol rose significantly 
(P<0.01) in both groups (55.3% in group I and 50.0% in group II) and in the course of 
the study HDL·) cholesterol levels slightly decreased in group Π but remained 
significantly higher than baseline values (P<0.05) whereas in group I the rise sustained. 
Furthermore, serum concentrations of HDL3 cholesterol rose significantly in both groups 
(group I: 18.1%, P<0.01; group II: 11.2%, P<0.05). Serum triglycerides rose with 
22.2% (P<0.05) in group I and with 12.0% (P>0.05) in group II and similar increases, 
though statistically not significant, were seen in very low-density lipoprotein triglycerides 
levels. During the study period apolipoprotein Α-I rose significantly (P<0.01) in both 
groups (group I: 23.0%, group II: 14.8%; Figure 2) whereas the apolipoprotein В 
concentrations remained similar. 
The atherogenic indices (Table ΙΠ) apolipoprotein B/apolipoprotein Α-I, LDL 
cholesterol/HDL cholesterol and total cholesterol/HDL cholesterol all decreased 
significantly in both groups (P<0.01). 
Table III: Atherogenic indices in group I and II a 
baseline 
0.90 ± 0.21 
0.98 ± 0.23 
2.88 ± 0.85 
3.08 ± 0.87 
4.36 ± 1.03 
4.66 ± 0.99 
cycle 3 
0.74 ± 0.21*·5 
0.79 ±0.19* 
2.16 ±0.73* 
2.35 ± 0.66* 
3.61 ± 0.98* 
3.86 ± 0.89* 
cycle 6 
0.75 ± 0.22* 
0.82 ± 0.22* 
2.21 ± 0.74* 
2.46 ± 0.75* 
3.64 ± 0.99* 
3.94 ± 0.92* 
cycle 13 
0.75 ± 0.22* 
0.80 ± 0.22* 
2.20 ± 0.69* 
2.44 ± 0.80* 
3.67 ± 0.96* 
3.92 ± 0.98* 
Group I (N=18): conjugated oestrogens 0.625 mg only; Group II (N=15): conjugated oestrogens 
0.625 mg and cyclic medrogestone 5 mg on days 17-28 of the 28 days treatment regimen. 
a
: values are means ± SD; statistics by s : Student paired t test (differences versus baseline) and 
ANOVA (ANW: within-group changes; ANB: between-group differences); $: P<0.01 ; 
Atherogenic indices: apolipoprotein B/apolipoprotein Α-I (Apo B/A), LDL cholesterol/HDL 
cholesterol (LDL/HDL), and total cholesterol/HDL cholesterol (TC/HDL). 
Apo B/A 
I 
LDL/HDL 
II 
TC/HDL 
II 
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DISCUSSION 
The hormone replacement regimen with continuous conjugated oestrogens and 
cyclic medrogestone as used in this study has been described as effective and satisfactory 
concerning relief of climacteric complaints and symptoms [15,16]. It has also been 
described as being effective in inducing secretory changes in a proliferative endometrium 
[17]. 
The purpose of this study was to investigate possible changes in serum lipids, 
lipoproteins and apolipoproteins during the given combination therapy and to determine 
any additional effect attributable to the cyclic administration of medrogestone. As to the 
latter, no significant differences were found between the lipid parameters measured during 
the treatment with conjugated oestrogens alone and combination therapy with conjugated 
oestrogens and cyclic medrogestone, except for serum HDL2 cholesterol concentrations. 
Since the difference in HDL cholesterol between the study groups was 10%, no statistical 
significance can be expected considering the sample size estimation. In order to detect 
small differences as observed in this study, and reach statistical significance, one should 
include at least 80 women in each study group. Although our findings are in agreement 
with earlier reports [6-8] there were clear differences in the design of the study. In our 
study we supplemented conjugated oestrogens 0.625 mg instead of 1.25 mg [6,7], with 
continuously administered conjugated oestrogens instead of using a pill-free interval [7,8]. 
Teichmann et al. [6] described a cyclic treatment regimen of "22 + 6 days" of which the 
nature can not be clearly understood. They found small but significant increases in HDL 
cholesterol and apolipoprotein Α-I whereas Sonnendecker et al. [8] found significantly 
increased levels of HDL cholesterol and HDL2 cholesterol and significantly decreased 
levels of total cholesterol and LDL cholesterol. After thirteen cycles of hormone 
treatment we found in both groups a significant increase in serum levels of HDL 
cholesterol, HDL2 and HDL3 cholesterol, where in group I the rise in HDL2 cholesterol 
was significantly stronger (P<0.05) then in group Π (Figure 1). Concerning the value of 
HDL subfraction analysis, Gordon et al. [18] found a consistent inverse relation between 
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HDL cholesterol levels and coronary heart disease event rates. According to Demacker et 
al. [19] the tedious subfractionation of HDL fails to add more information to that of total 
HDL cholesterol, and any rise can be regarded as beneficial. On the other hand, HDL·) 
cholesterol is the most variable part of HDL cholesterol, and its determination could 
enhance the discriminatory power to find statistical differences [20]. Indeed, HDL2 
cholesterol showed the largest percentual changes, as compared to total HDL cholesterol 
and HDL3 cholesterol, and it was the only variable in which significant differences were 
found between the changes in both groups. This difference may indicate a less beneficial 
effect on HDL2 cholesterol due to the addition of medrogestone. However, despite of this 
difference, HDL2 cholesterol rose in both groups, which can be considered as beneficial 
with regard to the risk of developing coronary heart disease. This also applies for the 
changes in HDL cholesterol and HDL3 cholesterol as found in this study, whereas HDL2 
cholesterol demonstrated the most potential to detect differences between the two groups. 
Serum LDL cholesterol decreased in both groups, even though the decrease in group I 
was not statistically significant after thirteen cycles. Serum triglyceride levels rose but 
remained below 2 mmol/l. In this study apolipoprotein Α-I, which is the main carrier 
protein of HDL, rose significantly and in parallel with HDL cholesterol in both groups 
(Figure 2) as was described by Teichmann et al. [6], but was not found by Sonnendecker 
et al. [8]. Teichmann et al. also found a decrease in apolipoprotein В in contrast to our 
findings. The changes in the calculated atherogenic indices indicate in another way the 
beneficial effect on the lipoproteins of both treatment regimen. 
Therefore, in both treatment groups changes in lipoprotein levels occurred which 
can be considered as beneficial with regard to the development of cardiovascular disease: 
a rise in HDL cholesterol and its major apolipoprotein, apolipoprotein Α-I, while 
apolipoprotein В remained unchanged. Except for HDL2 cholesterol no other significant 
differences were observed between the two study groups, but this may, however, be the 
result of the small sample size. To draw a firm conclusion on this issue it is 
recommended to extend the study with larger study groups. 
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CHANGES IN THE LOW-DENSITY LIPOPROTEIN PROFILE 
DURING 17ß-OESTRADIOL - DYDROGESTERONE THERAPY 
IN POSTMENOPAUSAL WOMEN 
M.J. van der Mooren, J. de Graaf, P.N.M. Demacker, A.F.J, de Haan, R. Rolland 
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ABSTRACT 
Introduction: Postmenopausal women are at increased risk for developing coronary 
heart disease (CHD) most likely due to alterations in plasma lipoproteins modulated by 
hormonal changes. Oestrogen supplementation may exert a protective role on CHD partly 
by the beneficial effects of oestrogens on lipid metabolism. Especially a rise in high-
density lipoprotein (HDL) is considered as a beneficial change whereas an increase in 
low-density lipoprotein (LDL) indicates an increased risk for developing CHD. Also LDL 
subfractions have been suggested to be of importance in the development of 
atherosclerosis. 
Objective: To study the changes in the LDL subfraction profile during postmenopausal 
hormone replacement therapy. 
Design: An open-label, non-comparative, prospective study. 
Patients: Twenty-three healthy non-hysterectomised postmenopausal women. 
Intervention: Continuous oral supplementation with 17ß-oestradiol, 2 mg daily, and 
cyclic administration of dydrogesterone, 10 mg daily for the first 14 days of each 28 days 
treatment cycle. 
Duration: One year. 
Measurements: LDL subfractions, as found by gradient gel electrophoresis. Changes 
were studied by visual observation of the gels and by analysis of the densitometric scans 
of the gels. 
Results: During treatment we observed significant changes in the LDL subfraction 
profile towards a smaller particle size (P<0.001). These changes could almost completely 
be attributed to the hormonal treatment regimen (P<0.01). 
Conclusions: The observed changes in LDL particle size may indicate an effect, 
partially opposite to the other reported changes in the lipid profile. However, it appears 
that a shift in LDL particle distribution to a smaller size may not per se be positively 
correlated with cardiovascular disease. There is a need for more prospective research 
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towards the effects of hormone replacement therapy in the protection against 
cardiovascular disease. 
INTRODUCTION 
Hormone replacement therapy (HRT) reportedly has been described to reduce the 
risk of developing coronary heart disease (CHD) in postmenopausal women, which may 
be partly due to the beneficial changes in the lipid profile [1,2]. 
Small low-density lipoprotein (LDL) particles are associated both with the male 
sex and increased age [3], and have also been identified as risk factor for CHD [4-6]. 
We studied possible changes in the LDL subfraction profile, as found by gradient 
gel electrophoresis (GGE), in healthy postmenopausal women during one year of HRT. 
The changes were related to those in serum lipids, lipoproteins and apolipoproteins. 
SUBJECTS AND METHODS 
The study was approved by the ethical committee of our hospital and before study 
entry the participants gave their written informed consent. Recruited were 23 healthy non-
hysterectomised postmenopausal women (mean age 54.3 yrs; SD 3.5 yrs), who were 
amenorrhoea for at least six months (mean 56 mths; SD 40 mths) and who were screened 
to have serum follicle-stimulating hormone (FSH) concentrations within the range, 
characteristic for the postmenopausal phase (mean 84 IU/1; SD 26 IU/I). Selection criteria 
and assays have been described elsewhere [7]. 
All women were treated with micronised 17ß-oestradiol (Zumenon®), 2 mg daily, 
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and with dydrogesterone (Duphaston®), 10 mg daily for the first half of each 28 days 
treatment cycle, both orally administered (Solvay Duphar, Weesp, The Netherlands). 
Determination of the LDL subfraction profile was performed in venous blood 
samples (evacuated collection tubes; Corvac®, Becton Dickinson, 38241, Cedex, France), 
taken after a twelve hours fast, before and after one year of HRT in all 23 women who 
completed the one year study period. Sera were stored at -80CC until the end of the 
study, and then assayed. Storage under these conditions has been shown not to influence 
the LDL subfraction profile [3,8]. 
LDL subtractions were separated by GGE as described previously [8], using 2-
16% Polyacrylamide gradient gels (PAA 2/16 gels; Pharmacia, Uppsala, Sweden). Serum 
aliquote were mixed with glycerol and bromphenol blue. Gels were pre-electrophoresed 
for 20 min at 70 V, afterwards we added 10 μ.1 of the prepared samples to each lane of 
the gel, and electrophoresis was continued for another 30 min at 70 V, followed for 5.5 h 
at 400 V and 8°C. After electrophoresis the gels were fixated in ethanol and the 
lipoprotein bands were stained with Sudan Black В (Paragon Lipostain; Beekman 
Instruments) followed by destaining in ethanol. Samples of the same subject were run on 
the same gel and in two nearest lanes. A serum standard was prepared by pooling sera to 
cover the complete spectrum of subfractions. In each gel this serum was applied in two 
lanes to serve as reference for the LDL bands in the samples. The pooled serum consisted 
of sera of six persons with a predominant LDL-1 (d: 1.030 to 1.033 kg/1), LDL-2 (d: 
1.033 to 1.040 kg/1), or LDL-3 (d: 1.040 to 1.045 kg/1) subfraction [8]. 
Changes in the LDL banding pattern with respect to change in the migration 
distance, reflecting LDL particle size, and the relative intensity, reflecting relative 
concentration, of each band were judged qualitatively by unblinded, but independent, 
visual inspection of the gels by three of the authors. 
Gels were also analysed quantitatively after densitometric scanning in triplicate 
with the LKB 2202 Ultrascan XL enhanced laser densitometer. The scans were analysed 
by calculating the change in relative peak height after therapy to determine changes in the 
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relative contribution of each LDL subfraction to total LDL. Furthermore, we evaluated 
the change in the migration distance and relative peak height of the predominant LDL 
band. 
Statistical analysis 
All changes were tested by means of the Wilcoxon signed-rank test. Qualitative 
changes in the LDL banding pattern, with respect to change in the migration distance and 
the relative intensity of each band, determined by visual inspection were tested with the 
sign-test. Inter-observer agreement on qualitative changes was measured by calculating the 
Λαρρα-coefficient [9]. Stepwise multiple regression analysis was used to examine 
significant contributions of serum lipids and (apo)lipoproteins to the variation in the LDL 
subfraction profile. By using the test on the intercept we examined whether HRT had a 
significant additional influence on the LDL subfraction profile. Statistical analyses were 
performed with the Statistical Analysis System software package (SAS Institute Inc., 
Сагу, NC). 
RESULTS 
Lipids and lipoproteins 
During the hormone therapy mean LDL cholesterol decreased from 4.47 (SD 1.52) 
to 3.84 (SD 1.02) mmol/1 (P<0.001), parallel with the decrease in total cholesterol from 
6.32 (SD 1.46) to 5.91 (SD 1.00) mmol/1 (P<0.01). High-density lipoprotein (HDL) 
cholesterol increased from 1.49 (SD 0.28) to 1.68 (SD 0.35) mmol/1 (P<0.001), while 
serum triglycerides (TG) increased slightly, but significantly (P<0.05) from 1.27 (SD 
0.69) to 1.45 (SD 0.73) mmol/1. Apolipoprotein (Apo) Α-I increased from 1417 (SD 191) 
to 1672 (SD 195) mg/1 (P< 0.001), while Apo В showed a slight non-significant decrease 
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from 1589 (SD 434) to 1554 (SD 398) mg/1. Lipoprotein(a) decreased from 303 (SD 467) 
to 239 (SD 382) mg/1 (P<0.001). 
LDL subfraction profile 
GGE of the individual sera revealed discrete LDL subfraction bands, that were 
identified as LDL-1, LDL-2 and LDL-3, with particle sizes of on average 267 Â, 257 Á 
and 251 Ä, respectively (data originating from work by Austin et al. [5]) (see Figure). 
This predominance of three LDL subfractions was confirmed by densitometric scanning of 
the gels. Each lane was scanned in triplicate. Within all triplicates, the number of peaks 
and the migration distance of each peak agreed well, and the shapes of the densitometric 
curves were similar. 
Visual inspection of the gels revealed that during the therapy in 48% (P<0.05) of 
the gels a shift in the total LDL profile towards a smaller LDL particle size was observed 
by all three observers (Table). In 74% similar observations were made by all the three 
authors (kappa = 0.69; SE = 0.10) with respect to change in the migration distance and 
relative intensity of each band. According to the calculated fazßpa-coefficient there was a 
substantial interobserver agreement [9]. 
Before treatment the mean percentual contributions of each LDL band to total 
LDL, calculated as mean relative peak heights, were: LDL-1: 36% (SD 22%; median 
34%, Qj 19%, Q3 55%), LDL-2: 44% (SD 18%; median 41%, Q, 28%, Q3 55%), LDL-
3: 20% (SD 15%; median 15%, Q1 11%, Q3 23%), and the predominant peak: 59% (SD 
9%; median 58%, Q¡ 51%, Q3 63%). In 21 individuals (91%) the predominant peak was 
the LDL-1 or LDL-2 peak. 
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Figure: Effect of HRT on the LDL subfraction profile of one subject as observed by 
gradient gel electrophoresis and densitometric scanning of the gel. 
During HRT the size of the LDL shifts towards a predominance of smaller LDL 
particles: 
Top: Upper part (40%) of one gel showing the VLDL and LDL range, covering 
the molecular size between 180 A and 800 A. 
Bottom: Middle: lanes of one subject before (B) and after (A) HRT, and of the 
pool serum (P), as shown in the frame (top). Left: densitometric scan of the gel 
before HRT. Right: densitometric scan of the gel after HRT. 
1: LDL-1 (267 Á); 2: LDL-2 (257 À); 3: LDL-3 (251 Á); *: Lp(a)-band; The 
values of molecular size distribution of the main subfractions originate from 
Austin et al. (réf. 5). 
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Table: Qualitative observations3 of changes in the LDL banding profileb related 
to particle size 
Author 
II m 
Three Similar 
Observations 
irticle size0 
Increase 
No change 
Decrease 
2 
8 
13 e 
2 
8 
13 e 
4 
6 
13 d 
2 
4 
11 
(9%) 
(17%) 
(48%) 
Total 23 23 23 17 (74%) 
a: independent visual observations by three of the authors; b: with respect to changes in 
the migration distance (reflecting LDL particle size), and the relative intensity (reflecting 
relative concentration), of each band; c: changes are described as change in LDL particle 
size; changes tested with the sign-test: d: P<0.05; e: P<0.01 (decrease versus increase 
in particle size); f: inter-observer agreement measured by tappa-coefficient: kappa = 
0.69 (SE = 0.10); N = 23. 
Further, analysis of data obtained by densitometric scanning revealed that HRT was 
associated with on average a small decrease in the mean relative heights of the LDL-1 
(mean -4%, SD 16%; median -4%, Q¡ -14%, Q3 +1%; P=0.154) and LDL-2 (mean -
3%, SD 18%; median + 1 % , Q¡ -22%, Q3 +10%; P=0.930) peaks in combination with 
a considerable increase in the relative height of the LDL-3 peak (mean +7%, 5D 12%; 
median +5%, Q¡ +1%, Q3 +7%; P=0.0005). So, the relative contribution of LDL-3 to 
total LDL increased, indicating a more dense subfraction profile. The mean relative 
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height of the predominant peak decreased significantly (mean -5%, SD 14%; median -5%, 
Q, -14%, Q3 0%; P=0.025) and its relative migration distance increased (mean +0.21 
units, SD 0.58 units; median +0.13 units, Q, -0.20 units, Q3 +0.70 units; />=0.131), 
reflecting a change towards a smaller LDL particle size. Thus, during HRT the average 
size of the LDL particles decreased. 
Stepwise regression analysis on all lipids and (apo)lipoproteins described in the 
results section, revealed that only total serum Apo В levels (as determined by 
nephelometry) correlated significantly to the relative height of the LDL-3 peak (P<0.05). 
An estimate of the additional effect of the given HRT on the relative height of the LDL-3 
peak, as found by the test on the intercept, is 0.08 (SE=0.02) (Р<0.01). So, HRT had a 
significant additional influence on the relative height of the LDL-3 peak. 
DISCUSSION 
Earlier, we reported on the changes in serum lipids and (apo)lipoproteins during 
sequential 17B-oestradiol - dydrogesterone therapy in postmenopausal women. With 
regard to the risk for CHD, these changes can be considered to be favourable with the 
exception of the small rise in the serum TG [7]. The concentration of LDL cholesterol 
decreased while that of total serum Apo B, which in these normo-triglyceridemic women 
is largely present in LDL, remained almost similar. The observed changes in the LDL 
cholesterol/Apo В ratio indicate a shift towards smaller LDL particles [3]. This could 
indeed be confirmed by GGE, a method which has proved to be valid for detecting LDL 
heterogeneity [8]. Recently, Campos et al, who already demonstrated smaller LDL 
particles in postmenopausal women [10], also reported decreased LDL cholesterol, and 
increased HDL cholesterol, Apo Α-I and TG levels in postmenopausal women treated 
with conjugated oestrogen monotherapy. In women with predominantly large LDL 
particles ( > 272 Â) they found a significant decrease in the LDL peak area and in the 
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particle diameter, while in women with predominantly small LDL particles (261-272 Λ) 
these parameters did not change [11]. 
A possible explanation for decreasing LDL particle size during HRT is given by 
Deckelbaum et al. [12] who hypothesized that size and density of LDL are at least partly 
determined by exchange of TG from very low-density lipoprotein (VLDL) for cholesteryl 
esters from LDL. As TG levels rise during oestrogen supplementation, due to increased 
VLDL synthesis, the hypothesized mechanism explains how LDL particles become 
enriched by an excess amount of TG at the expense of cholesteryl esters, and then allow 
continued particle size reduction through lipase action, which may finally result in lipid 
poor, and thus protein enriched LDL particles of relatively high density. 
A predominance of small LDL particles has earlier been identified in a lipoprotein 
pattern with increased serum TG and decreased HDL cholesterol levels [3]. In previous 
studies comparing LDL particle size of patients with CHD and controls [4-6] the LDL 
particle size difference between these two groups was reduced to non-significant after 
adjusting for TG and HDL cholesterol levels. This indicates that small LDL particles may 
not independently be associated with CHD. The reported association with low HDL 
cholesterol and elevated TG suggests that the LDL size reflects a series of alterations, that 
is deviating in CHD. Indeed, LDL of different size, induced by lipid exchange reactions, 
differ in their susceptibility to oxidative modification in vitro [13], a phenomenon 
considered to underlie the excessive accumulation of cholesterol in atherosclerotic lesions 
[14]. 
HRT, including the hormone treatment used in the present study, is associated 
with beneficial changes in the lipid and lipoprotein parameters predicting the risk for 
CHD [7]. The favourable effect of HRT concerning the risk for atherosclerosis is 
supported by animal experiments in which it was shown that LDL cholesterol 
accumulation in the arterial wall is attenuated by oestrogen monotherapy and combined 
oestrogen-progestogen therapy, even when plasma lipids, lipoproteins and apoproteins 
remain unchanged [IS]. As a matter of fact, also in these animal studies a decrease in 
LDL molecular weight was observed [IS]. 
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In summary, as a result of the diversity of influences on women's metabolism 
exerted by HRT, it remains difficult to make a proper CHD risk estimation, based on the 
common lipid parameters. From earlier reports on changes in LDL density and LDL 
particle size during HRT in experimental and clinical studies, that can be confirmed by 
our own observation, it appears that a shift in LDL particle distribution to a smaller size 
may not per se be positively correlated with cardiovascular disease. Clearly, there is a 
need for more prospective research towards the effects of HRT in the protection against 
cardiovascular disease. 
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ABSTRACT 
Introduction: Postmenopausal women are at increased risk for developing 
cardiovascular disease as compared to premenopausal women. During hormone 
replacement therapy the risk of developing cardiovascular disease decreases up to 50%. 
Homocysteine is an established independent risk factor for cardiovascular disease. 
Conflicting reports have indicated possible elevated homocysteine concentrations in 
postmenopausal women when compared to premenopausal women. 
Objective: To investigate the possible changes in fasting serum total homocysteine 
concentrations during hormone replacement therapy. 
Study Design: In a prospective study 21 healthy non-hysterectomised postmenopausal 
women were given continuous micronised 17ß-oestradiol, 2 mg daily, in combination with 
cyclic dydrogesterone, 10 mg daily during the first 14 days of each 28 days cycle. 
Changes were followed for up to two years. 
Results: During the first six cycles mean serum homocysteine decreased by 10.9% 
(P=0.013), after which no further significant changes were found during the two years of 
treatment. A 16.9% decrease (P=0.017; N=8) was found in women with high 
homocysteine concentrations, while in women with low homocysteine concentrations 
(N=13) no significant changes were observed. 
Conclusion: The observed decrease in high homocysteine concentrations in 
postmenopausal women may in part contribute to the decreased risk of developing 
cardiovascular disease during hormone replacement therapy. 
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INTRODUCTION 
Cardiovascular morbidity and mortality are important health problems in 
developed countries. In men the risk of cardiovascular disease (CVD) increases 
proportionally with age, while women are relatively protected until menopause. After 
menopause the risk of CVD increases rapidly. Menopause is hormonally characterised by 
decreasing serum oestrogen concentrations. Furthermore, serum concentrations of total 
cholesterol and low-density lipoprotein cholesterol increase, while high-density lipoprotein 
cholesterol decreases after menopause [1]. During postmenopausal hormone replacement 
therapy (HRT) the risk of developing CVD decreases up to 50% [1,2]. This has been 
partly explained by the beneficial changes in the lipid profile [3]. 
Elevated blood concentrations of homocysteine are an established independent risk 
factor for premature vascular disease [4-6]. Several investigators have reported increased 
homocysteine concentrations in postmenopausal women when compared to premenopausal 
women [7-9]. This observation, however, could not be confirmed by others [10-13]. 
Elevated homocysteine concentrations may in part contribute to the increased risk of 
developing CVD after menopause [8]. 
To investigate a possible effect of HRT on homocysteine concentrations, we 
studied the changes in fasting serum total (free and protein-bound) homocysteine 
concentrations during two years of supplementation with a sequential 17B-oestradiol -
dydrogesterone regimen in postmenopausal women. 
PATIENTS AND METHODS 
The study was approved by the ethical committee of our hospital on beforehand. 
Included were healthy non-hysterectomised postmenopausal women, who were 
amenorrhoeic for at least six months. Excluded from study were women using drugs 
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affecting lipid metabolism or women who used hormonal therapy for the previous two 
weeks. Previous to study entry, assessment of serum follicle-stimulating hormone (FSH) 
concentrations, liver enzymes (alanine aminetransferase, aspartate aminotransferase and 
gamma-glutamyltranspeptidase) and mammography were performed, and were found to be 
normal. Before entering the study the purpose of the protocol had been explained to the 
participants and written informed consent was obtained. None of the women reported 
intake of vitamin B6, B12, or folate supplements at study entry, or during the course of 
the study. 
After screening, 27 healthy postmenopausal women, aged 49 to 59 years, were 
included in the study. All women were given micronised 17fl-oestradiol (Zumenon®), 2 
mg daily, and cyclic dydrogesterone (Duphaston®), 10 mg daily for the first half of each 
28 days cycle, both orally administered (Solvay Duphar, Weesp, The Netherlands). 
Twenty-three women completed the two-year study period. The reasons for exclusion of 
four women have been reported elsewhere [14]. Another two women had to be excluded 
from statistical analyses because their serum FSH concentrations (18 and 26 IU/1, 
respectively) appeared too low for the range, characteristic for the postmenopausal phase 
(FSH ä 40 IU/1). Therefore, statistical analyses were performed on data of 21 women, 
with a mean age of 54.5 years (range: 49 - 59 years), who were amenorrhoeic for 55.1 
months (range: 9 - 120 months), and whose mean body-mass index was 24.4 kg/m2 
(range: 20.8 - 29.3 kg/m2). 
Physical examination and fasting venous blood sampling were performed before 
study entry and on day 12, 13 or 14 of the combined 17fl-oestradiol and dydrogesterone 
intake of cycles 6 (± 1) , 12 (± 1) and 24 (± 1). Blood sampling was performed after a 
12 hours fast. Furthermore, assessment of lipids and lipoproteins (total cholesterol, very 
low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, triglycerides, very low-density lipoprotein triglycerides, 
apolipoprotein Α-I, Α-Π, and B, and lipoprotein^)), coagulation factors (antithrombin III 
and fibrinogen) and glucose was performed to determine possible statistical correlations 
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with serum concentrations of total homocysteine. 
Serum concentrations of FSH were measured with a specific immunoradiometric 
assay (Medgenix, Fleuras, Belgium) as described elsewhere [15]. Serum concentrations of 
17ß-oestradiol were measured with an in-house radioimmunoassay [16] and serum 
concentrations of oestrone were measured by oestrogen-specific dextran-coated charcoal 
radioimmunoassay described by Heineman [17]. 
For serum total homocysteine measurement blood was drawn into evacuated 
collection tubes (Corvac®, Becton Dickinson, 38241, Cedex, France). After clotting for 
one to two hours, serum was isolated after centrifugation for 15 min at 3500 χ g. Sera 
were stored at -80CC until analysis. To minimize the imprecision of assay all samples 
from the same subject were analysed in the same run. Serum total homocysteine was 
measured by High Performance Liquid Chromatography (HPLC) and fluorimetrie 
detection according to Fiskerstrand et al. [18]. The detection limit was 0.5 /лпоі/і and the 
intra- and interassay coefficients of variation amounted both to < 5%. 
Assays on lipids, lipoproteins and coagulation factors have been described 
elsewhere [14]. 
Statistical analysis was performed on the data of 21 women. Hormonal parameters 
were tested by the Student paired t test. Homocysteine was tested by Friedman's two-way 
analysis of variance and Wilcoxon's signed-rank test. The P-values were two-tailed, and a 
P-value lower than 0.05 was considered to be statistically significant. Statistical analyses 
were performed with the Dyna-stat computer program (Dynamic Microsystems, Inc., 
Washington D.C., Pittsburgh, PA, USA). 
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RESULTS 
Hormonal parameters 
During the first six cycles of HRT the mean serum concentration of FSH 
decreased significantly with 52% and the mean serum concentrations of oestrone and 
oestradiol increased significantly 10-fold and 5-fold, respectively (Table 1). 
Table I: Serum concentrations of reproductive hormones before treatment (cycle 0) 
and on day 12, 13 or 14 of the combined 17fi-oestradiol - dydrogesterone 
therapy of cycle 6 a 
Cycle 0 Cycle 6 / * 
FSH (1U/1) 90 ± 18 43 ± 19 < 0.0001 
E t (pmol/l) 232 ± 75 2612 ± 1486 < 0.0001 
Ez (pmol/l) 104 ± 30 635 ± 3 1 0 < 0.0001 
a
: values as mean ± SD (N = 21); D: Student paired t test; E t: oestrone; Έχ. oestradiol. 
Serum homocysteine 
After the first six treatment cycles the mean concentration of serum homocysteine 
was significantly lower as compared to baseline {Total group: -10.9%; P=0.013) (Table 
2), after which no further statistically significant changes were observed during the two 
years of treatment. When dividing the total group in subgroups with homocysteine 
concentrations above the mean {High-level group: homocysteine > 13.8 μπιοΐ/l; N = 8) 
and below the mean {Low-level group: homocysteine < 13.8 /miol/1; N = 13), the High-
level group showed a 16.9% decrease (P=0.017), while in the Low-level group no 
significant changes were observed. 
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Figure: Individual changes in fasting serum total homocysteine concentrations during the 
first 12 treatment cycles with a sequential 17fl-oestradiol - dydrogesterone regimen 
(N = 21), · · High-level group (homocysteine > 13 8 μπιοΙ/Ι), · · 
Low-level group (homocysteine < 13 8 μπιοΐ/l) 
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No significant correlations were found between serum homocysteine and serum 
oestrogens, lipids and lipoproteins or coagulation factors. 
DISCUSSION 
We found significantly decreased serum homocysteine concentrations during HRT. 
To the best of our knowledge, this observation has not been reported before. The authors 
realize that their study design lacks a control group. However, a mean decrease of 11% 
in six months that sustained thereafter obviously excludes the possibility of a mere drift in 
time or variation due to storage. Earlier, it was demonstrated that homocysteine 
concentrations show little changes in time, when re-investigated after 6 - 1 2 months [10]. 
Differences in homocysteine concentrations have been demonstrated during 
pregnancy and during intake of oral contraceptives (OC). In pregnant women, having high 
oestradiol concentrations, homocysteine concentrations were found to be lower as 
compared to non-pregnant women [19,20]. Surprisingly, high concentrations of 
homocysteine have been found during the use of OC's [21], but this observation was not 
confirmed by others [22,23]. It must be emphasized that synthetic oestrogens like ethinyl-
oestradiol, which is the most common oestrogen in OC's, may have different metabolic 
interactions when compared with natural oestrogens, as used in the present 
postmenopausal HRT study. 
Until now the relationship between homocysteine metabolism and the hormonal 
changes in climacteric women has not been clearly established. Boers et al. [7] described 
the efficiency of the methionine metabolism in premenopausal women leading to lower 
homocysteine concentrations as compared to postmenopausal women. This has also been 
demonstrated by others [8,9]. However, some investigators reported non-significant 
differences [10,11], or no difference at all [12,13] between pre- and postmenopausal 
women. This may be due to differences in, or imprecision of the assay-procedure. Some 
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authors determined free homocysteine (homocysteine-cysteine mixed disulfide and 
homocystine) [7,8,13], while others determined total (free and protein-bound) 
homocysteine [9,11,12], or both [10]. Recently, we observed clearly elevated total plasma 
homocysteine concentrations, fasting as well as after methionine loading, in 
postmenopausal women when compared to premenopausal women [24]. Increased 
homocysteine concentrations may well in part contribute to the increased risk of 
developing CVD after menopause [8]. 
After six months of treatment, seven of eight women in the High-level group, and 
after 12 months all eight women showed a substantial decrease (average -18%; P=0.012) 
in serum homocysteine. In the Low-level group no significant changes were observed. 
This indicates that especially those women, having a higher homocysteine-related risk for 
CVD, may favour the homocysteine-lowering influence of HRT, while HRT does not 
seem to influence low-normal homocysteine concentrations. 
Elevated homocysteine concentrations have been related to an increased risk of 
developing CVD [4-6], but cardioprotective influences of homocysteine lowering therapy 
have not been published yet. Therefore, one can only speculate that the decrease in 
homocysteine concentrations in postmenopausal women due to HRT will have a 
cardioprotective influence. 
In conclusion, high serum homocysteine concentrations in postmenopausal women 
decreased during HRT. The observed decrease may in part contribute to the decreased 
risk of developing CVD during HRT. Still, there are many obscurities and controversial 
observations concerning the influence of sex hormones on the homocysteine concentration 
in postmenopausal women that warrant further investigation. 
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ABSTRACT 
Objective: To describe changes in the withdrawal bleeding pattern and endometrial 
histology during a sequential 17ß-oestradiol - dydrogesterone regimen in postmenopausal 
women. 
Design: Open-label, non-comparative, prospective study. 
Setting: Gynaecological outpatient department of a university hospital. 
Patients: Twenty-seven healthy non-hysterectomised postmenopausal women. 
Interventions: Continuous micronised 176-oestradiol supplementation, 2 mg daily, and 
cyclic administration of dydrogesterone, 10 mg daily for the first half of each 28 day 
treatment cycle. 
Main Outcome Measures: Changes in the characteristics of the withdrawal bleeding 
pattern and the endometrial biopsy histology during two years of treatment. 
Results: The initial withdrawal bleeds were comparable to normal menstruation with 
respect to amount and duration. During the two years of treatment the bleeding showed a 
significant tendency to become shorter with less blood loss. This was mainly the result of 
the decrease (P<0.001) in the number of days per cycle with bleeding grade II (normal 
menstruation). None of the women developed endometrial hyperplasia, and in almost all 
women the given hormone replacement therapy regimen induced secretory or atrophic 
changes of the endometrium. 
Conclusions: This sequential 17B-oestradiol - dydrogesterone regimen can be regarded 
as safe with respect to the prevention of endometrial disease. Furthermore, it appears to 
foster patient compliance. 
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INTRODUCTION 
Postmenopausal hormone replacement therapy (HRT) has become of increasing 
interest in general and gynaecologie practices, not only for its effective relief of 
climacteric and postmenopausal symptoms and complaints, but also for its important 
preventive effects on bone mineral loss and cardiovascular disease (CVD) [1-5]. 
Unopposed oestrogen therapy in non-hysterectomised women reportedly increases 
the incidence of irregular bleeding and the risk of developing endometrial hyperplasia and 
carcinoma. Nowadays, it is generally accepted practise to add a progestogen, either 
continuously or cyclical to the oestrogen therapy [6]. In Europe, the latter is the most 
commonly prescribed HRT regimen. The progestogen transforms the oestrogen-induced 
proliferative and hyperplastic endometrium into a secretory or even atrophic endometri-
um. Sequential HRT regimen, however, restore vaginal bleeding, which may reduce 
patient compliance. Furthermore, progestogens may attenuate the beneficial changes in 
lipid metabolism brought about by unopposed oestrogen therapy. The degree of 
attenuation depends on the type and the dosage of the progestogen, as well as the route 
and duration of its administration [7,8]. Therefore, the optimal oestrogen-progestogen 
combination prescibed for postmenopausal non-hysterectomised women must firstly 
garantee the safety of the treatment with regard to endometrial disease and limit vaginal 
bleeding, and secondly must induce beneficial changes in the lipid metabolism which 
favour CVD risk. 
Dydrogesterone has been described as a metabolic inert progestogen to have little 
or no influence on the lipid metabolism [9-12]. Recently, we reported on the changes in 
serum lipids and (apo)lipoproteins during two years of continuous supplementation of 
micronised 17ß-oestradiol and cyclic administration of dydrogesterone [13]. These 
changes were in favour of lowering the risk of developing CVD. In order to document the 
compliance and safety of this HRT regimen, we investigated the changes in characteristics 
of the withdrawal bleeding pattern, and studied the endometrial histology. 
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SUBJECTS AND METHODS 
The study received prior approval by the ethical committee of our hospital. 
Healthy non-hysterectomised postmenopausal women were recruited by advertisement in a 
local newspaper during the months January until May 1990. The women were 
amenorrhoeic for at least six months and were screened to have follicle-stimulating 
hormone (FSH) serum concentrations within the range, characteristic for the 
postmenopausal phase. Excluded were women using drugs affecting lipid metabolism or 
who used hormonal therapy for the previous two weeks. Before entering the study the 
purpose of the protocol had been explained and written informed consent was obtained. 
After screening 27 women, aged 49 - 59 years, were included in the study. 
Characteristics of the study population are given in Table I. In two cases the FSH and 
oestradiol concentrations exceeded the postmenopausal range (normal range: FSH: ä: 36 
IU/1; oestradiol: < 150 pmol/1) as a result of a short wash-out period (i.e. 2 weeks; 
FSH: 18 IU/1; oestradiol: 290 pmol/1) or a relatively short amenorrhea (i.e. 7 months; 
FSH: 26 IU/1; oestradiol: 820 pmol/1). 
Table I: Characteristics of the study population* 
Age 
Amenorrhea 
Body-mass index 
FSHb 
Oestradiol 
(years) 
(months) 
(kg/m2) 
(Ш/1) 
(pmol/1) 
54.0 
53 
24.5 
83 
145 
(49 - 59) 
(7 - 120) 
(20.1 -30.9) 
(18 - 140) 
(75 - 820) 
a
: values given as mean (range); N = 27; b : follicle-stimulating hormone. 
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All women were treated with micronised 17ß-oestradiol (Zumenon®), 2 mg daily, 
and with dydrogesterone (Duphaston®), 10 mg daily for the first half of each 28 day 
treatment cycle, both orally administered (Solvay Duphar, Weesp, The Netherlands). 
Before starting the study medication the women were at first given a progesterone 
challenge test (PCT), by administration of dydrogesterone 10 mg daily for 12 days. 
During the study the women recorded any vaginal bleeding on a diary card. 
Bleeding for which no sanitary protection was needed (spotting) was coded as bleeding 
grade I. Bleeding identified as being like normal menstruation was coded as grade Π, and 
heavy vaginal bleeding as grade III. 
Physical examination and endometrial biopsy took place before study entry and on 
day 12, 13 or 14 of the combined 17ß-oestradiol and dydrogesterone intake of cycles 12 
(± 1 cycle) and 24 (± 1 cycle). Endometrial biopsy was performed by micro-curettage 
(Vabra® endocurette, Farina Lanfranco, Venezia, Italia). Endometrial samples were 
collected in neutrally buffered formaldehyde solution (4%), and embedded in one paraffin 
block each. Six micrometer thin sections were cut and stained with haematoxylin and 
eosin for routine pathological examination. The slides were analysed and histological 
diagnosis was established by a consultant pathologist at the Institute of Pathology, 
University Hospital Nijmegen, The Netherlands, using strict histologic criteria. 
Twenty-three women completed the two year study period. One woman was 
incorrectly admitted to the study as the initial endometrial biopsy showed focal 
adenomatous hyperplasia. Therefore she was excluded. There were three drop outs due to 
various reasons [13]. 
In six women the dydrogesterone dosage was increased from 10 to 20 mg, 
according to instructions in the protocol, since repeated spotting or withdrawal bleeding 
occured before day ten of the combined 17ß-oestradiol and dydrogesterone intake [14]. 
Another woman missed dydrogesterone seven days in two cycles and fourteen days in one 
cycle, due to repeated hospitalisation because of total hip surgery, without further 
violation of the protocol. 
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Statistical analysis was performed on the data of all 27 women included on an 
"intention-to-treat" basis. The last visit carried forwards (LVCF) procedure was used 
because of one exclusion and three drop outs. To evaluate the withdrawal bleeding pattern 
the following characteristics were analysed: number of days per cycle with respectively 
bleeding grade I, grade II, grade III, and total bleeding days per cycle, the mean bleeding 
grade per cycle and the first cycle day of the withdrawal bleeding. The raw data of these 
bleeding characteristics showed the biggest changes during the first six months, while the 
second study year only showed a modest continuation of the trend seen in the second half 
of the first year. Therefore, for analysis of the bleeding characteristics it was decided to 
divide the two year study period into five intervals: cycle 1, cycles 2-3, cycles 4-6, cycles 
7-12 and cycles 13-24. All bleeding characteristics were analysed by Friedman's two way 
Analysis of Variance. 
Endometrial biopsy histology was categorized as: no passage to the uterine cavity 
achieved, insufficient tissue (for appropiate diagnosis), atrophic endometrium, secretory 
endometrium, proliferative endometrium and hyperplasia. Data on changes in endometrial 
histology are merely descriptive since the population size was too small to justify any 
statistical analysis. 
RESULTS 
Withdrawal bleeding pattern 
Of the 27 women five (19%) had a positive PCT after 12 days of dydrogesterone 
challenge, previous to treatment. During the study period the total number of bleeding 
days per cycle decreased, after an initial increase during the first three cycles, from 6.6 
{mean; SD 2.0) to 5.3 (SD 1.5) days per cycle (P=0.0001; cycle interval 2-3 versus 13-
24; see Figure). 
136 
Endometrium & Withdrawal Bleeding Pattern 
DAYS PER CYCLE 
2-3 4-6 7-12 13-24 
CYCLE INTERVAL 
Figure: Withdrawal bleeding pattern during 17B-oestradiol - dydrogesterone therapy in 27 
women. Bleeding characteristics: number of days per treatment cycle with 
respectively bleeding grade I (spotting; no protection needed), grade Π (normal 
menstruation), grade III (heavy vaginal bleeding), and standard deviation (error 
bars) of total bleeding days. 
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This fall could mostly be attributed to the reduction, also after an initial increase, in 
bleeding grade II, from 2.3 (SD 1.8) to 1.5 (SD 1.1) days per cycle (P<0.001; cycle 
interval 2-3 versus 13-24 ). No significant changes occurred in withdrawal bleeding grade 
I and ΙΠ. The mean bleeding grade per cycle decreased, after an initial increase, from 
1.44 (SD 0.35) to 1.36 (SD 0.25) (P<0.05; cycle interval 2-3 versus 13-24) and the 
mean first bleeding day was delayed with 1.4 days from cycle day 12.3 (SD 2.5) to cycle 
day 13.7 (SD 1.8) (P<0.05; cycle interval 2-3 versus 13-24). 
Endometrial histology 
The findings are summarized in Table II. Before treatment the initial endometrial 
biopsy of two women (7.4%) showed a proliferative endometrium, and they also had a 
positive PCT. Both women bled between five and eight days per cycle, one stopped the 
medication because of progressive varicosis, the other kept moderately heavy withdrawal 
bleeds (grade II and HI) until the end of the study period. Another woman's initial 
biopsy, also following a positive PCT, showed focal adenomatous hyperplasia, and she 
was therefore excluded from the study. Until the moment of exclusion she had regular 
withdrawal bleeds, and follow up biopsies showed no signs of hyperplasia. In the other 
two women with a positive PCT, and in whom the 10 mg dydrogesterone dosage had to 
be increased to 20 mg because of commencement of withdrawal bleeding before cycle day 
ten [14], the endometrium showed secretory changes after 24 treatment cycles. The other 
four women in whom the dydrogesterone dosage was increased showed secretory changes 
(N = 3; 11%) or an atrophic endometrium (N = 1). In 21 women the initial endometrial 
biopsies showed atrophic endometrial tissue (N = 1) or insufficient tissue for appropiate 
diagnosis (N = 20; 74%), which can in most cases be regarded as a symptom of the 
atrophic status of the postmenopausal endometrium. In three women (11%) no passage to 
the uterine cavity was achieved. 
After 12 treatment cycles the endometrium of 17 women (63%) showed secretory 
changes. After 24 treatment cycles the endometrial biopsies showed in most cases (N = 
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18; 67%) secretory changes, some in combination with slight proliferative changes. 
Further, atrophic tissue (N = 1) and insufficient tissue (N = 2) were observed, or no 
passage to the uterine cavity was achieved (N = 2). In none of the women hyperplastic 
changes of the endometrium were observed during the treatment. 
Table II: Endometrial histology before (cycle 0) and after 12 and 24 cycles of 
17ß-oestradiol - dydrogesterone therapy 
Category Cycle 0 Cycle 12 Cycle 24 
No passage* 
Insufficient tissue 
Atrophy 
Secretory 
Proliferative 
Hyperplasia 
Drop out/exclusion 
3 
20 
1 
. 
3 
2 
1 
17 
2 
2 
1 
18 
N = 27; a: no passage to the uterine cavity; . excluded from study. 
DISCUSSION 
Since Ziel & Finkle in 1975 [15] reported an increased risk of endometrial cancer 
during unopposed oestrogens, this finding has been confirmed by others [16-18], 
including the increased risk of endometrial hyperplasia. In modern HRT regimen, the 
addition of a progestogen, cyclical or continuously, has become generally accepted. The 
addition of a progestogen during at least 12 days per treatment cycle prevents the increase 
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in risk of hyperplasia or carcinoma due to oestrogen treatment [19-23]. Although both the 
cyclic and the continuous administration seem equally effective with regard to the latter, 
in Europe the cyclical regimen are more commonly prescribed. 
Dydrogesterone, a retroprogesterone, lacks the androgenic properties [24] as seen 
in many other progestogens, which is probably the reason why it does not affect the lipid 
profile unfavourably [10,12,13]. To establish secretory changes in the oestrogen-primed 
endometrium a daily dose of 10 to 20 mg is required [25-27]. Recently, it has been 
demonstrated that 14 days administration of 10 to 20 mg of dydrogesterone opposes the 
proliferative effects of a 50 mg oestradiol implant, and that 20 mg is sufficient to 
counteract the effects of a 100 mg oestradiol implant [28,29]. 
The present study demonstrates that the given sequential oestradiol-dydrogesterone 
regimen introduced a withdrawal bleeding that was initially comparable to normal 
menstruation with respect to amount and duration, and that during two years of treatment 
the bleeding showed a tendency to become shorter with less blood loss. The first can be 
concluded from the decrease in the total bleeding days per cycle, and the latter from the 
decrease in the number of days with bleeding grade II, and the decrease in the mean 
bleeding grade per cycle. These changes can be regarded as favourable with respect to 
patient compliance. Nineteen of the 23 women (83%) who completed the study desired to 
continue the treatment after the two year study period, which underlines the degree of 
patient acceptability. 
In six women (22%) with irregular blood loss, the dydrogesterone dosage had to 
be increased to 20 mg daily according to the protocol. This resulted in an acceptable 
bleeding pattern indicating that individualisation of HRT regimen is preferred to fixed-
dose HRT combinations. 
After two years of HRT with dydrogesterone, 10 or 20 mg for 14 days each 28 
day cycle, 19 of the 23 women who completed the study period (83%) showed a 
secretory or atrophic endometrium. Even in the one case that the initial biopsy showed 
focal adenomatous hyperplasia, a regular withdrawal bleeding partem and absence of 
hyperplastic or proliferative changes was established during cyclic administration of 10 
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mg dydrogesterone in combination with 17ß-oestradiol. 
In view of earlier demonstrated beneficial changes in serum lipids and 
(apo)lipoproteins during this sequential 17fi-oestradiol - dydrogesterone regimen, and the 
data presented here on bleeding pattern and endometrium histology, we conclude that this 
HRT regimen appears safe, promotes good compliance and is therefore well suited for the 
purpose of HRT. 
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GENERAL DISCUSSION 
Chapter 8 
For the purpose of treatment of climacteric complaints hormone replacement 
therapy is practisized for a long period of time. From the literature it is clear that 
hormone replacement therapy benefits the quality of a climacteric or postmenopausal 
woman's life. Especially the typical complaints as flushes and sweats, and the urogenital 
complaints due to the oestrogen deficiency, respond well to the supplementation of natural 
oestrogen. Also less typical complaints, for example sleep disturbances, forgetfulness, 
fatigue and melancholia, frequently related to the severity of flushes and sweats, often 
improve as well. 
In addition to the direct benefits of hormone replacement therapy on typical and 
atypical climacteric complaints there is also growing evidence on other favourable effects 
of hormone supplementation. Oestrogens appear to be a key hormone in bone metabolism 
and have proven effectivity in the prevention of osteoporosis. Addition of progestogens 
even may strengthen this effect on bone metabolism. Hormone replacement therapy has 
reduced the incidence of osteoporotic fractures in postmenopausal women. Large scale 
hormone prescription to postmenopausal women at risk for osteoporosis can be expected 
to have a high impact on the socio-economic consequences of oseoporosis. 
The literature contains an extensive amount of data indicating that oestrogen also is 
a key hormone in the regulation of cardiovascular function, and that oestrogen is of 
importance in secondary and probably also in primary prevention of cardiovascular 
disease. Hormone replacement therapy reduces cardiovascular disease risk with up to 
50%. Women at risk to develop cardiovascular disease due to obesity, smoking habits, 
hyperlipidaemia or history of coronary heart disease may benefit even more. 
These benefits have made hormone replacement therapy increasingly popular. 
However, the reported increased incidence of endometrial cancer in the past made 
oestrogen treatment less popular. Prolonged oestrogen exposure was associated with 
hyperplastic and carcinogenic changes in the endometrium. Better understanding of the 
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endometrial physiology led to the addition of cyclic progestogen administration in non-
hysterectomised women, which reduced the incidence of endometrial hyperplasia and 
carcinoma to frequencies even below those seen in untreated women [1]. Therefore, it is 
nowadays generally accepted to reserve unopposed oestrogen treatment only for 
hysterectomised women. Non-hysterectomised women should always be treated with a 
progestogen combined with the oestrogen therapy for at least 10 days. 
As stated before, the importance of progestogens for the safety of the endometrium 
is generally accepted, and the studied oestradiol-dydrogesterone regimen in this thesis was 
confirmative with other reports on the safety of dydrogesterone in this respect. However, 
the effects of progestogens on the other organ systems is yet unclear. Progestogens 
apparently do not protect the breasts against cancer, they even may stimulate the 
proliferation of breast glandular tissue [2]. Until recently it was believed that 
progestogens attenuate or even reverse the beneficial effects of oestrogen on lipids and 
lipoproteins. Therefore an unfavourable influence concerning the cardiovascular system 
seemed evident. 
In this thesis two combined oestrogen/progestogen treatments were investigated 
concerning their influences on lipids and lipoproteins: an oestradiol-dydrogesterone 
regimen and a conjugated oestrogen-medrogestone regimen. Both hormone treatments 
induced beneficial changes in the lipid profile. In both studies the additional effects of 
progestogens when combined with oestrogen were investigated. The progestogen 
administration did not induce unfavourable additional changes in lipids and lipoproteins. 
Until now this item was often neglected in the literature. Both studies dealt with rather 
small groups, which may have unpaired the statistical power. The observed changes in 
the oestradiol-dydrogesterone study were very clear and a larger population to prove the 
effectiveness of the treatment is not needed. The chapter on the conjugated oestrogen-
medrogestone treatment reported preliminary data from a larger study [3], that 
demonstrated almost comparable changes as described in this thesis. So, our studies on 
lipids and lipoproteins did not support the suggested unfavourable progestogenic influence 
on the cardiovascular system, in agreement with other recent reports [4-8]. 
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The reported effects of hormone treatment on the conventional lipid and 
lipoprotein risk estimators can only be held responsible for about 25% of the 
cardiovascular risk reduction, and more research on other risk factors is needed to 
elucidate this intriguing matter. In this thesis three new risk factors in the field of 
cardiovascular research in postmenopausal women were studied: lipoprotein(a), the low-
density lipoprotein profile and the homocysteine metabolism. The decrease in 
lipoprotein(a) very well adds to the other beneficial changes in the lipid profile. Still, 
evidence is lacking that reducing lipoprotein(a) decreases cardiovascular risk. The 
observed changes in the low-density lipoprotein profile during hormone treatment are 
confirmative with some earlier reports, but the demonstrated shift towards smaller low-
density lipoprotein particles is still difficult to integrate with the changes in the other 
lipids and lipoproteins. Apparently, in our understanding so far the observed shift 
indicates an unfavourable influence of the hormone treatment, but the significance of this 
effect when compared with the substantial increase in high-density lipoprotein cholesterol, 
and decreases in total low-density lipoprotein cholesterol and lipoprotein(a) is 
questionable. Further research on hormone induced changes in the low-density lipoprotein 
profile, and also changes in its oxidizability, is yet ongoing. The first data indicate that 
hormone supplementation does reduce low-density lipoprotein oxidizability [9], which can 
be regarded as favourable in respect to this lipoprotein's atherogenicity. In contrast to the 
low-density lipoprotein profile, the study of hormonal effects on serum homocysteine is 
still unique. Until now the literature on hormone related changes related to menopause in 
homocysteine concentrations are scarce and inconsistent. Very recently, our research 
group reported substantial differences in total plasma homocysteine, fasting and after 
methionine loading, between healthy pre- and postmenopausal women [10]. At least in 
part this observation may help to explain the difference in cardiovascular risk between 
pre- and postmenopausal women. This thesis demonstrates that above normal 
homocysteine concentrations in postmenopausal women decrease with 17% during 
hormone replacement therapy, while low normal homocysteine concentrations do not 
change. Therefore, it may be important to identify women that are at risk for developing 
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cardiovascular disease related to the high homocysteine concentration, since these women 
may benefit the homocysteine reducing influence of hormone supplementation. 
Unpublished data of evidence in a new trial confirm these findings [11]. Неге, a 10% 
decrease in mean homocysteine concentration was measured during a sequential 
conjugated oestrogen and medrogestone treatment. Therefore, it is likely that a decrease 
in homocysteine may explain part of the reduction in cardiovascular disease in hormonally 
treated postmenopausal women. Our results on the observed reduction in homocysteine 
concentrations during hormone replacement therapy pleads for recognition of 
homocysteine metabolism in further postmenopausal research. 
For the prevention of osteoporosis hormone treatment for at least five years is 
advised, while only a small percentage of women is taking the treatment longer than two 
years [12]. With respect to cardiovascular disease, the relation between treatment duration 
and preventive effects is yet unclear, but it seems justified to think of a comparable 
necessarry minimal period of treatment. Especially with respect to the aspects of 
secundary prevention life-long treatment needs consideration. Regarding the apparent 
problem of patient compliance, at least in non-hysterectomised women, patient compliance 
reportedly was inversely correlated with the inconvenience of the withdrawal bleeds. To 
improve compliance, the bleeding aspects of existing treatments need to be evaluated, and 
new research must help to find ways to reduce the bleeds in duration, frequency and 
severity. In this thesis we demonstrate that during monthly sequential oestradiol-
dydrogesterone treatment the withdrawal bleeding is acceptable and shows a tendency to 
become shorter with less blood loss, which favours the acceptance of the treatment. This 
was also confirmed by the high percentage of women that asked to continue the treatment 
after two years of hormone replacement. 
Alternative treatment modalities have been introduced, such as the continuous 
combined oestrogen-progestogen treatment. Although promising for women that are 
postmenopausal for one or more years, this treatment still needs thorough evaluation, 
primarily concerning its effects on the endometrium and the bleeding aspects, but also 
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with respect to its consequences for osteoporosis, cardiovascular disease and the breast 
disease. Recent investigations on endometrial receptor kinetics may be promising with 
respect to the development of alternative treatment regimen with combined oestrogen and 
interrupted progestogen administration [13]. A prolonged treatment cycle, inducing 
withdrawal bleeds every two or three months instead of every month, may offer a 
reasonable alternative. Although prolonged treatment cycles seem common practise for 
general practitioners and gynaecologists, literature data on this issue are very scarce. 
Presently, new studies investigating three-monthly treatment regimen, with respect to their 
effects on the endometrium and the bleeding pattern, as well as the metabolic effects, are 
ongoing in our department [14]. 
From the review of the literature and the data from our own studies it can be 
concluded that the benefit/risk ratio of hormone replacement therapy is in favour of the 
benefits. Nevertheless, still many aspects of this type of treatment are uptill now 
unknown, especially the long-term effects. It has to be kept in mind that hormone 
treatment at present with a tendency toward long-term prescription on a larger scale must 
take place under regular medical supervision. Only by systematic medical follow up any 
undesired effect can be diagnosed. This also garantees an adequate registration as a basis 
for future epidemiological evaluation. 
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SUMMARY 
The first chapter gives a short introduction and describes the aim of the thesis. 
The second chapter of this thesis reviews some aspects of hormone replacement 
therapy. The main indications and contra-indications for hormone replacement therapy are 
discussed, after which the cardiovascular impact of hormone treatment and the possible 
underlying pathogenetic mechanisms are reviewed. Furthermore, the role of progestogens, 
and its consequences for patient compliance are considered. 
The third chapter describes the effects of a sequential 17ß-oestradiol-
dydrogesterone therapy on serum lipids and lipoproteins in 27 women. Part I of chapter 
3 reports on the changes after the first year of this two-year study. The observed changes 
in lipids and lipoproteins were in favour of the prevention of cardiovascular disease. 
Furthermore, no deterioration in coagulation parameters or glucose metabolism was 
found. Part Π of chapter 3 reports the results after two years of treatment. The changes 
observed after 6 months remained stable for the remainder of the study period. No 
differences were found between the oestradiol-only phase and the combined oestradiol-
dydrogesterone phase of the last treatment cycle studied. So, the progestogen 
dydrogesterone did not attenuate the oestrogen induced beneficial changes in serum lipids 
and lipoproteins. 
The sequential conjugated oestrogen-medrogestone treatment was described in 
chapter 4. Also this therapy induced favourable changes in the serum lipids and 
lipoproteins with respect to the prevention of developing cardiovascular disease, and 
except for HDL^-cholesterol, no significant differences were found between the combined 
oestrogen-progestogen treatment and the unopposed oestrogen treatment, indicating that 
medrogestone lacks an undesirable effect on the lipid profile. 
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In chapter 5 the effect of the sequential 17fl-oestradiol-dydrogesterone treatment 
on the low-density lipoprotein profile, determined by gradient gel electrophoresis, was 
described. We found a significant shiñ within the low-density lipoprotein profile towards 
a smaller low-density lipoprotein particle size. Although such a shift repeatedly has been 
associated with an increased cardiovascular risk, this implication is questioned with 
respect to our finding, since the observed shift in our patients was accompanied with clear 
favourable changes in the conventional lipid and lipoprotein risk estimators. In the 
discussion this point of view is illustrated by referring to data based on animal 
experiments and other experimental studies aimed to gain insight into the effect of 
hormone supplementation on atherosclerosis. All these studies illustrate the anti-
atherogenic effect of hormone supplementation. 
In chapter б a possible non-lipoprotein etiology for cardiovascular disease is 
introduced. Elevated homocysteine concentrations are an independent cardiovascular risk 
factor. Some studies indicated that in postmenopausal women homocysteine levels are 
higher than in premenopausal women, which phenomenon may explain part of the 
increased cardiovascular morbidity and mortality after menopause. During the sequential 
17ß-oestradiol-dydrogesterone treatment a significant decrease in mean fasting total serum 
homocysteine of 11% was demonstrated. Those women with high homocysteine 
concentrations demonstrated a 17% decrease, while women with low homocysteine 
concentrations showed no changes. It is suggested that this observation may in part 
explain the cardioprotective effect of hormone replacement therapy. The importance of 
more research on homocysteine metabolism in relation to hormonal changes in 
perimenopausal women and during postmenopausal hormone replacement therapy is 
advocated. 
Safety aspects of the endometrium and the changes in the withdrawal bleeding 
pattern during the sequential 17B-oestradiol-dydrogesterone treatment were investigated in 
chapter 7. Histological analysis of endometrial biopsy samples showed no undesirable 
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hyperplastic or carcinogenic changes in all 27 women studied. The withdrawal bleeds 
were acceptable, and showed a tendency to become shorter with less blood loss during the 
two years of treatment. Furthermore, more than 80% of women asked to continue the 
hormone treatment after the two-year study period. These findings are promising with 
respect to patient acceptance of the treatment, and this again may be decisive to achieve 
the long-term treatment benefits for osteoporosis and the cardiovascular system. 
In chapter 8 the results of the present thesis are integrated in the latest 
developments in the field of postmenopausal research. The literature supplies an 
increasing amount of evidence about the benefits of hormone replacement therapy. 
Nevertheless, still many aspects of this kind of treatment are incompletely understood. 
This chapter emphasizes the need for future research, with special reference to studies 
towards other possible pathogenetic mechanisms explaining the cardioprotective effects of 
hormone supplementation, and to studies investigating new treatment regimen that may 
help to improve patient acceptance and compliance. 
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SAMENVATTING 
In hoofdstuk 1 wordt een introductie gegeven en de doelstellingen van de thesis 
worden uiteengezet. 
In hoofdstuk 2 van dit proefschrift worden een aantal aspecten betreffende 
hormonale suppletie therapie samengevat. De belangrijkste indicaties en contra-indicaties 
voor hormoon suppletie worden besproken, waarna de cardiovasculaire impact van 
hormoon behandeling en de mogelijk hieraan ten grondslag liggende pathogenetische 
mechanismen worden toegelicht. Tevens wordt ingegaan op de rol van progestagenen, en 
de consequenties hiervan voor de therapie compliance en de acceptatie door de patiënt. 
Hoofdstuk 3 beschrijft de effecten van een sequentiële L7ß-oestradiol-
dydrogesteron behandeling op de serum lipiden en lipoproteïnen in 27 vrouwen. In deel I 
van hoofdstuk 3 worden de veranderingen genoemd die werden gevonden na het eerste 
jaar van deze 2 jaar durende behandeling. De gevonden veranderingen in lipiden en 
lipoproteïnen waren gunstig met betrekking tot de preventie van het ontstaan van 
cardiovasculaire ziekten. Tevens werd geen verstoring gevonden van de stollings 
parameters of het glucose metabolisme. Deel Π van hoofdstuk 3 beschrijft de resultaten 
na 2 jaar behandeling. De geconstateerde veranderingen in lipiden and lipoproteïnen 
traden reeds op na 6 maanden, en bleven hierna onveranderd gedurende 2 jaar. Er werden 
geen verschillen gevonden tussen de oestradiol-alleen fase en de gecombineerde 
oestradiol-dydrogesteron fase van de laatste behandelcyclus. Dus, het progestageen 
dydrogesteron had geen nadelige invloed op de gunstige veranderingen in de lipiden en 
lipoproteïnen, teweeggebracht door het oestrogeen. 
Een sequentiële geconjugeerde oestrogenen-medrogeston behandeling wordt 
beschreven in hoofdstuk 4. Ook deze behandeling veroorzaakte gunstige veranderingen in 
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de serum lipiden en lipoproteïnen met betrekking tot de preventie van het ontstaan van 
cardiovasculaire ziekten. Met uitzondering van het HDI^-cholesterol werden er geen 
significante verschillen gevonden tussen de gecombineerde oestrogeen-progestageen 
behandeling en de oestrogeen-alleen behandeling, dus medrogeston heeft geen nadelige 
effecten op het lipiden profiel. 
De effecten van de sequentiële 17ß-oestradiol-dydrogesteron behandeling op het 
low-density lipoprotéine profiel, bepaald met gradiënt gel electrophorese, worden 
beschreven in hoofdstuk 5. Er werd een significante verschuiving binnen het low-density 
lipoprotéine profiel waargenomen in de richting van een kleinere partikel grootte van het 
low-density lipoprotéine. Alhoewel een dergelijke verschuiving in de literatuur is 
geassocieerd met een toegenomen cardiovasculair risico, wordt deze associatie betwijfeld 
met betrekking tot onze bevindingen, aangezien de waargenomen verschuiving wordt 
vergezeld door uitgesproken gunstige veranderingen in de conventionele lipiden en 
lipoproteïnen. In de discussie wordt dit standpunt toegelicht aan de hand van 
experimentele studies welke het effect van hormoon suppletie op athérosclérose 
onderzocht hebben. AI deze studies demonstreren een anti-atherogeen effect van 
hormonale suppletie therapie. 
In hoofdstuk 6 wordt een niet-lipoproteïne etiologie van cardiovasculaire ziekten 
geïntroduceerd. Verhoogde homocysteine concentraties zijn een onafhankelijke 
cardiovasculaire risicofactor. Sommige studies hebben bij postmenopauzale vrouwen 
hogere homocysteine concentraties aangetoond dan bij premenopauzale vrouwen. Dit 
fenomeen zou voor een deel het gestegen cardiovasculaire risico na de menopauze kunnen 
verklaren. Tijdens de sequentiële 17fl-oestradiol-dydrogesteron behandeling werd een 
significante daling van 11% gemeten in de gemiddelde concentratie van het nuchter totaal 
serum homocysteine. Vrouwen met een hoog homocysteine hadden een daling van 17%, 
terwijl vrouwen met een laag homocysteine geen verandering ondergingen. Er wordt 
gesuggereerd dat deze bevinding mogelijk een deel van het cardioprotectieve effect van 
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hormonale suppletie therapie zou kunnen verklaren. Het belang van meer onderzoek op 
het gebied van het homocysteine metabolisme in relatie met de hormonale veranderingen 
rond de menopauze en tijdens postmenopauzale hormoon suppletie wordt aanbevolen. 
De veiligheidsaspecten met betrekking tot het endometrium en de veranderingen in 
het bloedingspatroon tijdens de sequentiële 17ß-oestradiol-dydrogesteron behandeling 
worden beschreven in hoofdstuk 7. Histologisch onderzoek van endometrium, verkregen 
door middel van microcurettage, in 27 vrouwen vertoonde geen tekenen van hyperplasie 
of maligniteit. De onttrekkingsbloedingen waren acceptabel, en tijdens de 2 jaar durende 
behandeling werd een trend geconstateerd naar een kortere bloeding met minder 
bloedverlies. Meer dan 80% van de deelneemsters wenste de hormoon behandeling na 
afloop van het onderzoek voort te zetten. Deze bevindingen zijn van groot belang met 
betrekking tot de acceptatie van de behandeling, en dit is wederom van doorslaggevende 
betekenis voor het kunnen bereiken van de voordelen van lange-termijn behandeling 
inzake osteoporose en het cardiovasculaire systeem. 
In hoofdstuk 8 worden de resultaten van dit proefschrift geïntegreerd binnen de 
laatste ontwikkelingen op het gebied van postmenopauze research. In de literatuur worden 
vele gegevens aangedragen ten gunste van hormoon suppletie. Desalniettemin blijkt onze 
kennis ten aanzien van vele aspecten van hormonale suppletie therapie onvoldoende. Dit 
hoofdstuk benadrukt het belang van meer onderzoek, in het bijzonder onderzoek naar 
mogelijke nieuwe pathogenetische mechanismen die het cardioprotectieve effect van 
hormoon suppletie kunnen verklaren, en verder onderzoek naar nieuwe behandelschema's 
die acceptatie van de behandeling en de compliance kunnen verbeteren. 
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Monique Brood (Duphar Nederland BV), Frederike Sieders (Wyeth-Ayerst 
Research & Development) en Hilde Kornaat (Wyeth Laboratoria BV) voor de prettige 
samenwerking en het zorgvuldig monitoren van de onderzoeken. 
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examen werd in 1980 behaald aan het Christelijk Atheneum te Arnhem. Vanaf 1981 werd 
de geneeskunde opleiding gevolgd aan de Katholieke Universiteit Nijmegen alwaar het 
arts-examen werd behaald op 13 januari 1989. 
Na als AGNIO chirurgie werkzaam te zijn geweest op twee lokaties van het 
Rijnstate Ziekenhuis te Arnhem werd hij in april 1990 aangesteld als arts-onderzoeker 
binnen de afdeling Obstetrie & Gynaecologie van het Academisch Ziekenhuis Nijmegen 
Sint Radboud, alwaar onder leiding van Prof.dr. R. Rolland een aanvang werd gemaakt 
met de onderzoeken die de basis vormen van dit proefschrift. Deze werkzaamheden 
werden tijdelijk afgewisseld door een AGNIO aanstelling binnen de kliniek. 
Tijdens de afronding van dit proefschrift werd een aanvang gemaakt met meerdere 
nieuwe trials, zowel op het gebied van postmenopauzale hormoonsuppletie als op het 
gebied van de ontwikkeling van nieuwe orale anticonceptiva. Hij zal voorlopig zijn 
onderzoeksaktiviteiten binnen de afdeling voortzetten. 
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Stellingen 
behorende bij het proefschrift 
Hormone Replacement Therapy 
Metabolic and Endometrial Changes, and the Role of Progestogens 
1. Tijdens sequentiële hormoonsuppletie met de combinatie van zowel gemicroniseerd 
17fl-oestradiol en dydrogesteron, als van geconjugeerde oestrogenen en medrogeston, 
treden gunstige veranderingen op in de serum concentraties van lipiden en 
lipoproteïnen. (dit proefschrift) 
2. Tijdens hormoonsuppletie neemt de partikel-grootte van de low-density lipoproteïnen 
af. De betekenis van deze verandering is nog geenszins duidelijk. (dit proefschrift) 
3. Er zijn aanwijzingen dat het homocysteine metabolisme een rol speelt in de preventieve 
effecten van hormoonsuppletie bij postmenopauzale vrouwen. (dit proefschrift) 
4. Tijdens sequentiële hormoonsuppletie met 17ß-oestradiol in combinatie met maandelijks 
dydrogesteron wordt binnen 2 jaar behandeling de onttrekkingsbloeding korter van duur 
en lichter van intensiteit. (dit proefschrift) 
5. In de discussie betreffende het al dan niet natuurlijk zijn van hormoonsuppletie dient 
men zich te realiseren dat het afraden danwei onthouden van een "onnatuurlijke" 
therapie kan leiden tot een verhoogde kans op gezondheidrisico's samenhangend met de 
"natuurlijk" optredende oestrogeendeficiëntie. 
6. Bij therapietrouw speelt tijd een essentiële rol, waarbij echter niet alleen aan de tijd van 
de patiënt dient te worden gedacht. 
7. De ontwikkeling van orale contraceptiva met natuurlijke oestrogenen biedt wellicht de 
mogelijkheid reeds tijdens de premenopauzale jaren te profiteren van de geconstateerde 
preventieve effecten hiervan op hart- en vaatziekten. 
8. Met het oog op de beperkte financiële middelen die er bestaan voor het verrichten van 
medisch wetenschappelijk onderzoek verdient samenwerking met de farmaceutische 
industrie een positieve benadering. 
9. Bij de behoefteraming voor gynaecologen/obstetrici tot het jaar 2005 zijn 
demografische ontwikkelingen, deeltijdwerk, afname van de werkweek en een toename 
van niet-patiêntgebonden activiteiten betrokken*. De recente ontwikkelingen inzake 
zwangerschapsbevorderende technieken bij perimenopauzale vrouwen dienen hierbij in 
de toekomst niet miskend te worden. 
(* Hingstman L, et al. Ned Tijdsch Geneesk 1994;138:969-973) 
10. Een vloeiende overgang is niet per definitie een probleemloze. 
Nijmegen, 13 oktober 1994 Marius Jan van der Mooren 


